WO2012160855A1 - Injection needle assembly and drug injection device - Google Patents

Injection needle assembly and drug injection device Download PDF

Info

Publication number
WO2012160855A1
WO2012160855A1 PCT/JP2012/055940 JP2012055940W WO2012160855A1 WO 2012160855 A1 WO2012160855 A1 WO 2012160855A1 JP 2012055940 W JP2012055940 W JP 2012055940W WO 2012160855 A1 WO2012160855 A1 WO 2012160855A1
Authority
WO
WIPO (PCT)
Prior art keywords
needle
syringe
tube
needle tube
medicine
Prior art date
Application number
PCT/JP2012/055940
Other languages
French (fr)
Japanese (ja)
Inventor
倫子 鹿角
陽一郎 岩瀬
横田 崇之
Original Assignee
テルモ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テルモ株式会社 filed Critical テルモ株式会社
Publication of WO2012160855A1 publication Critical patent/WO2012160855A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/46Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for controlling depth of insertion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/31Details
    • A61M5/32Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/34Constructions for connecting the needle, e.g. to syringe nozzle or needle hub
    • A61M5/347Constructions for connecting the needle, e.g. to syringe nozzle or needle hub rotatable, e.g. bayonet or screw

Definitions

  • the present invention relates to an injection needle assembly and a drug injection device in which a syringe in which a drug is contained and an air vent is performed can be attached.
  • prefilled syringes in which a medicine is prefilled in a syringe are often used.
  • Such a prefilled syringe does not require an operation of sucking the drug from the vial into the syringe at the time of drug administration, and thus it is possible to reduce the time required for drug administration.
  • Patent Document 1 discloses a prefilled syringe including a syringe body filled with a medicine and a cap attached to the syringe body and sealing the medicine in the syringe body.
  • a needle hub to which the injection needle is fixed is attached to the medicine discharge portion which is the tip of the prefilled syringe, and the proximal end of the injection needle is communicated with the inside of the syringe body.
  • medical agent is discharged
  • a skin contact portion capable of adjusting the depth of puncture of the injection needle is provided in order to perform stable puncture.
  • the air is vented after the syringe is attached to the needle hub, the liquid droplet leaks from the tip of the injection needle, and the chemical adheres between the skin contact portion and the skin contact portion and the needle tube. There is a fear. For this reason, it is also conceivable to vent the syringe before attaching the syringe to the needle hub.
  • the present invention has been made in view of the above points, and an object of the present invention is to provide an injection needle assembly to which a syringe that has been evacuated can be attached, and a medicine injection device using the injection needle assembly.
  • an injection needle assembly includes a needle tip that is pierced into the skin and a needle tube having a proximal end opposite to the needle tip. Also, it has a medicine filled inside and a discharge part for discharging the medicine, a fitting part into which a discharge part of a syringe in a state where air is discharged from the inside is inserted, a needle tube holding the needle tube, A needle hub having a holding portion for positioning the proximal end at the fitting portion.
  • the cap which covers the needle tip of a needle tube is provided. The inner wall surface of the cap is provided with a collection unit that collects liquid droplets leaking from the needle tip.
  • the drug injection device is a device in which a syringe is attached to the above-described injection needle assembly.
  • This syringe has a medicine filled inside and a discharge part for discharging the medicine, and air is discharged from the inside.
  • the recovery unit that recovers the liquid droplet leaking from the needle tip is provided on the inner wall surface of the cap. For this reason, even if the syringe which filled the inside with the chemical
  • the injection needle assembly and the drug injection device of the present invention it is possible to suppress the formation of liquid droplets at the needle tip of the needle tube, so that a syringe filled with the drug and exhausted air is attached in advance. Is possible. For this reason, the operation
  • FIG. 1 is an exploded view of a medicine injection device 100 according to the present embodiment.
  • the drug injection device 100 is used when the needle tip is punctured from the surface of the skin and, for example, the drug is injected into the upper layer of the skin.
  • the drug injection device 100 includes an injection needle assembly 1 and a syringe 2 connected to the injection needle assembly 1 and filled with a drug (medicine solution).
  • the injection needle assembly 1 includes a hollow needle tube 3 having a needle hole, a needle hub 4 to which the needle tube 3 is fixed, an elastic member 7 disposed in the needle hub 4, and a detachable attachment to the needle hub 4. And a cap 5 for protecting the needle tube 3.
  • the needle hub 4 includes a first member 6 that holds the needle tube 3 and a second member 8 into which a later-described discharge portion 42 of the syringe 2 is inserted.
  • the needle tube 3 of the injection needle assembly 1 has a size of 26 to 33 gauge (outer diameter 0.2 to 0.45 mm) according to the ISO medical needle tube standard (ISO9626: 1991 / Amd.1: 2001 (E)). Those of 30 to 33 gauge are preferably used.
  • FIG. 2 is a cross-sectional view showing a state in which the syringe 2, the needle tube 3, and the needle hub 4 are assembled.
  • a needle tip 3 ⁇ / b> A having a blade surface 3 a is provided at one end of the needle tube 3.
  • the other end of the needle tube 3 opposite to the needle tip 3A is referred to as a “base end 3B”.
  • the axial length of the needle tube 3 on the blade surface 3a (hereinafter referred to as “bevel length”) may be 1.4 mm (adult) or less, which is the thinnest thickness of the upper skin portion described later, What is necessary is just about 0.5 mm or more which is the bevel length when a short bevel is formed in a 33 gauge needle tube. That is, the bevel length is preferably set in the range of 0.5 to 1.4 mm.
  • the bevel length is further preferably such that the thinnest thickness of the upper skin layer is 0.9 mm (child) or less, that is, the bevel length is in the range of 0.5 to 0.9 mm.
  • the short bevel refers to a blade surface that is generally used for injection needles and forms an angle of 18 to 25 ° with respect to the longitudinal direction of the needle.
  • the material of the needle tube 3 examples include stainless steel, but are not limited thereto, and aluminum, aluminum alloy, titanium, titanium alloy, and other metals can be used.
  • the needle tube 3 can be not only a straight needle but also a tapered needle having at least a part tapered. As the tapered needle, the proximal end has a larger diameter than the needle distal end, and the intermediate portion may have a tapered structure. Further, the cross-sectional shape of the needle tube 3 may be not only a circle but also a polygon such as a triangle.
  • the first member 6 and the second member 8 of the needle hub 4 are formed as separate members, but may be formed integrally.
  • Examples of the material of the first member 6 and the second member 8 include synthetic resins such as polycarbonate, polypropylene, and polyethylene.
  • the first member 6 includes a base portion 9, an adjustment portion 10, a stabilization portion 11, and a guide portion 12.
  • the first member 6 is configured as a holding unit that holds the needle tube 3.
  • the base portion 9 is formed in a substantially cylindrical shape and has end faces 9a and 9b perpendicular to the axial direction.
  • the adjustment unit 10 is provided at the center of the end surface 9 a of the base unit 9, and includes a columnar projection that protrudes in the axial direction of the base unit 9.
  • the axis of the adjustment unit 10 is coincident with the axis of the base unit 9.
  • a through hole 13 through which the needle tube 3 passes is provided in the axial center of the base portion 9 and the adjustment portion 10.
  • the base portion 9 is provided with an injection hole 15 for injecting the adhesive 14 into the through hole 13.
  • the injection hole 15 is opened on the outer peripheral surface of the base portion 9 and communicates with the through hole 13. That is, the needle tube 3 is fixed to the base portion 9 by the adhesive 14 injected from the injection hole 15 to the through hole 13.
  • the proximal end 3B side of the needle tube 3 protrudes from the end surface 9b of the base portion 9.
  • the base portion 9 is inserted into the second member 8 from the end surface 9b side, and the proximal end 3B side of the needle tube 3 is inserted into an insertion hole 71 described later of the elastic member 7.
  • the end surface 9b of the base part 9 is contact
  • a connecting piece 16 is provided on the outer peripheral surface of the base portion 9.
  • the connection piece 16 is formed as a ring-shaped flange projecting in the radial direction of the base portion 9, and has flat surfaces 16 a and 16 b facing the axial direction of the base portion 9.
  • the second member 8 is connected to the flat surface 16 b of the connection piece 16. Further, the distal end portion of the connection piece 16 is a guide portion 12. The guide portion 12 will be described in detail later.
  • the end surface of the adjusting portion 10 is a needle protruding surface 10a from which the needle tip 3A side of the needle tube 3 protrudes.
  • the needle projecting surface 10 a is formed as a plane orthogonal to the axial direction of the needle tube 3.
  • the needle protruding surface 10a defines the depth of puncturing the needle tube 3 in contact with the skin surface when the needle tube 3 is punctured into the upper skin portion. That is, the depth at which the needle tube 3 is punctured into the upper skin layer is determined by the length of the needle tube 3 protruding from the needle protruding surface 10a (hereinafter referred to as “projection length L”).
  • the thickness of the upper skin portion corresponds to the depth from the skin surface to the dermis layer, and is generally in the range of 0.5 to 3.0 mm. Therefore, the protruding length L of the needle tube 3 can be set in the range of 0.5 to 3.0 mm.
  • the vaccine is generally administered to the upper arm, but in the case of administration to the upper skin part, the shoulder peripheral part where the skin is thick, particularly the deltoid part is preferable.
  • the thickness of the upper layer of the deltoid muscle of 19 children and 31 adults was 0.9 to 1.6 mm.
  • the thickness of the upper skin layer of the deltoid muscle of adults was 1.4 to 2.6 mm at the distal part, 1.4 to 2.5 mm at the central part, and 1.5 to 2.5 mm at the proximal part. It was.
  • the protruding length L of the needle tube 3 is preferably set in the range of 0.9 to 1.4 mm.
  • the blade surface 3a of the needle tip 3A can be reliably positioned on the upper skin portion.
  • the needle hole (medicine discharge port) that opens in the blade surface 3a can be located in the upper skin layer portion at any position within the blade surface 3a. Even if the medicine discharge port is located in the upper skin layer, if the needle tip 3A is stabbed deeper than the upper skin layer, the medicine flows subcutaneously between the side surface of the end of the needle tip 3A and the cut skin. Therefore, it is important that the blade surface 3a is surely in the upper skin portion.
  • the needle projecting surface 10a is formed such that the distance S from the peripheral edge to the outer peripheral surface of the needle tube 3 is 1.4 mm or less, preferably in the range of 0.3 to 1.4 mm.
  • the distance S from the peripheral edge of the needle protruding surface 10a to the peripheral surface of the needle tube 3 is set in consideration of the pressure applied to the blisters formed by administering the drug to the upper skin layer. That is, the needle protruding surface 10a is set to a size that is sufficiently smaller than the blisters formed in the upper skin layer and does not hinder the formation of blisters. As a result, even if the needle protruding surface 10a presses the skin around the needle tube 3, it is possible to prevent the administered medicine from leaking.
  • the stabilizing part 11 is formed in a cylindrical shape protruding from the flat surface 16 a of the connecting piece 16 provided on the base part 9.
  • the needle tube 3 and the adjustment unit 10 are disposed in the cylindrical hole of the stabilization unit 11. That is, the stabilizing portion 11 is formed in a cylindrical shape that covers the periphery of the adjusting portion 10 through which the needle tube 3 passes, and is provided away from the needle tip 3A of the needle tube 3 in the radial direction.
  • the end surface 11a of the stabilizing portion 11 is located closer to the proximal end 3B side of the needle tube 3 than the needle protruding surface 10a of the adjusting portion 10.
  • the needle protruding surface 10 a contacts the surface of the skin, and then contacts the end surface 11 a of the stabilizing portion 11.
  • the drug injection device 100 is stabilized by the end surface 11a of the stabilizing portion 11 coming into contact with the skin, and the needle tube 3 can be maintained in a posture substantially perpendicular to the skin.
  • the stabilizing portion 11 is formed with a first vent hole 17 penetrating from the outer peripheral surface to the inner peripheral surface.
  • the adjustment portion 10 is also provided with a second ventilation hole 18 that penetrates the side surface thereof and communicates with the through hole 13.
  • the first ventilation hole 17 and the second ventilation hole 18 constitute a space surrounded by the stabilizing portion 11 and the skin and a ventilation means for opening the through hole 13 to the outside.
  • the needle tube 3 is skinned. It is possible to keep the posture substantially perpendicular to the angle.
  • the axial distance between the end surface 11a of the stable portion 11 and the needle protruding surface 10a is preferably set to 1.3 mm or less.
  • the inner diameter d of the stable portion 11 is set to a value equal to or larger than the diameter of the blister formed on the skin.
  • the distance T from the inner wall surface of the stable portion 11 to the peripheral edge of the needle protruding surface 10a is set to be in the range of 4 mm to 15 mm. Thereby, it can prevent that blister formation is inhibited by pressure being applied to the blister from the inner wall surface of the stable part 11.
  • the distance T from the inner wall surface of the stable portion 11 to the peripheral edge of the needle protruding surface 10a is not particularly limited as long as it is 4 mm or more. However, when the distance T is increased, the outer diameter of the stable portion 11 is increased, so that it becomes difficult to bring the entire end surface 11a of the stable portion 11 into contact with the skin when the needle tube 3 is punctured into a thin arm like a child. . For this reason, the distance T is preferably set to 15 mm as a maximum in consideration of the thinness of the child's arm.
  • the adjusting unit 10 does not enter the skin. Therefore, considering the distance T (4 mm or more) from the inner wall surface of the stable portion 11 to the periphery of the needle protruding surface 10a and the diameter (about 0.3 mm) of the needle protruding surface 10a, the inner diameter d of the stable portion 11 is 9 mm or more. Can be set.
  • the shape of the stable part 11 is not limited to a cylindrical shape, and may be formed in a rectangular tube shape such as a quadrangular column or a hexagonal column having a cylindrical hole at the center.
  • the guide portion 12 is a portion on the peripheral side with respect to the position of the stable portion 11 in the connection piece 16.
  • the guide portion 12 has a contact surface 12a that comes into contact with the skin.
  • the contact surface 12 a is a part of the flat surface 16 a of the connection piece 16 and is a flat surface that is substantially parallel to the end surface 11 a of the stabilizing portion 11.
  • the distance Y from the contact surface 12a of the guide portion 12 to the end surface 11a of the stable portion 11 punctures the needle tube 3 and the stable portion 11 by pressing the skin with an appropriate pressing force. Its length is set so that it can.
  • the guide portion 12 guides the pressing force applied to the skin by the needle tube 3 and the stabilizing portion 11, and the needle tip 3A (blade surface 3a) of the needle tube 3 can be reliably positioned on the upper skin portion of the skin. Can give you a sense of security.
  • An appropriate pressing force of the needle tube 3 and the stable portion 11 is, for example, 3 to 20N.
  • the guide portion height Y is the length from the tip surface of the guide portion 12 to the outer peripheral surface of the stable portion 11 (hereinafter referred to as “guide portion length”). It is determined appropriately based on X. For example, when the inner diameter d of the stable portion 11 is 12 mm and the guide portion length X is 3.0 mm, the guide portion height Y is set in the range of 2.3 to 6.6 mm.
  • the cap 5 (see FIG. 1) is detachably fitted to the guide portion 12.
  • the cap 5 covers the needle tip 3 ⁇ / b> A of the needle tube 3.
  • needle tip 3A can be prevented from touching a user's fingertip.
  • the used medicine injection device 100 or the needle assembly 1 can be always kept in a safe state, and the user can safely dispose of the used medicine injection device 100 or the needle assembly 1 or the like. It can be carried out.
  • the second member 8 is formed in a substantially cylindrical shape.
  • One end portion of the second member 8 in the axial direction is an insertion portion 19 into which the base portion 9 of the first member 6 is inserted, and the other end portion is in the insertion portion 20 into which the discharge portion 42 of the syringe 2 is inserted. It has become.
  • the cylindrical hole 19 a of the insertion portion 19 is set to a size corresponding to the base portion 9 of the first member 6.
  • the insertion part 19 is provided with a fixing piece 21 connected to the connection piece 16 of the first member 6.
  • the fixed piece 21 is formed as a ring-shaped flange that protrudes radially outward continuously from the tip of the fitting portion 20.
  • a flat surface 16 b of the connection piece 16 provided on the first member 6 is brought into contact with and fixed to the fixed piece 21.
  • Examples of the fixing method of the fixing piece 21 and the connection piece 16 include an adhesive, ultrasonic welding, laser welding, and a fixing screw.
  • the cylinder hole 20a of the insertion part 20 is set to a size corresponding to the discharge part 42 of the syringe 2, and the diameter continuously decreases toward the insertion part 19 side.
  • a thread groove 22 for screwing the discharge part 42 of the syringe 2 is formed on the inner surface of the fitting part 20.
  • a stopper 23 that protrudes toward the axis of the cylindrical hole 20 a is provided closer to the insertion portion 19 than the screw groove 22.
  • the discharge portion 42 of the syringe 2 is locked by the stopper 23, thereby preventing further insertion of the syringe 2.
  • a gap is provided between the end face 42a of the discharge portion 42 and the base end 3B of the needle tube 3 in the axial direction of the tube hole 20a.
  • a hub side display unit 25 is provided on the outer peripheral surface of the insertion unit 20 as a recognition unit for recognizing that the insertion of the discharge unit 42 is completed.
  • the hub side display part 25 coincides with a syringe side display part 44 (described later) provided in the discharge part 42 in the circumferential direction of the second member 8.
  • the second member 8 of the needle hub 4 is formed of a transparent or translucent synthetic resin so that the syringe-side display portion 44 can be visually recognized through the fitting portion 20.
  • a convex part is provided in one base end of the thread part 43 of the syringe 2 or the thread groove 22 of the insertion part 20, and the recessed part engaged with the convex part is made into the other base end. You may form by providing. In this case, it is possible to recognize that the insertion of the discharge portion 42 into the insertion portion 20 is completed by the engagement between the convex portion and the concave portion.
  • the engaging portion 24 is formed as a step portion protruding radially inward from the inner surface of the second member 8, and has engaging surfaces 24 a and 24 b that are substantially orthogonal to the axial direction of the second member 8. .
  • a first flange portion 72 (to be described later) of the elastic member 7 is engaged with the engagement surface 24a of the engagement portion 24, and a second flange portion 73 of the elastic member 7 is engaged with the engagement surface 24b.
  • the elastic member 7 is disposed in the second member 8 of the needle hub 4 and is interposed between the first member 6 that holds the needle tube 3 and the syringe 2.
  • the elastic member 7 includes a main body portion 70, a first flange portion 72 provided at one end of the main body portion 70 in the axial direction, and a second flange portion 73 provided at the other end of the main body portion 70. is doing.
  • the main body 70 is formed in a substantially cylindrical shape and has end faces 70a and 70b perpendicular to the axial direction.
  • the end surface 9 b of the base portion 9 of the first member 6 is in contact with the end surface 70 a of the main body portion 70.
  • the end surface 70b of the main-body part 70 is spaced apart from the end surface 42a of the discharge
  • the main body portion 70 is provided with an insertion hole 71 through which the proximal end 3B side of the needle tube 3 protruding from the end surface 9b of the base portion 9 of the first member 6 is inserted.
  • the insertion hole 71 extends in the axial direction of the main body 70 and is opened to the end faces 70a and 70b.
  • the inner surface of the main body portion 70 is formed by a base side separation portion 74, a syringe side separation portion 75, and a close contact portion 76.
  • the base side separation portion 74 forms an opening of the insertion hole 71 in the end surface 70a.
  • the base-side separation portion 74 is separated from the outer peripheral surface of the needle tube 3 and is formed in a tapered shape such that the diameter of the insertion hole 71 continuously increases toward the end surface 70a. Thereby, the base end 3 ⁇ / b> B side of the needle tube 3 protruding from the end surface 9 b of the base portion 9 can be easily inserted into the insertion hole 71.
  • the shape of the base-side separation portion 74 in the insertion hole 71 is not limited to a tapered shape as long as the needle tube 3 can be easily inserted into the insertion hole 71.
  • the syringe side separation part 75 forms the opening of the insertion hole 71 in the end surface 70b.
  • the syringe-side separation portion 75 is separated from the outer peripheral surface of the needle tube 3, and is formed in a taper shape such that the diameter of the insertion hole 71 continuously increases toward the end surface 70b.
  • a needle-side valve element 77 is provided in the syringe-side separation part 75.
  • the needle side valve body 77 is formed as a cylindrical protrusion that covers the outer periphery of the needle tube 3.
  • the outer peripheral surface of the needle side valve body 77 is formed in a taper shape whose diameter continuously decreases toward the tip.
  • the contact portion 76 is formed between the base side separation portion 74 and the syringe side separation portion 75.
  • the contact portion 76 is in liquid-tight contact with the outer peripheral surface of the needle tube 3, and the medicine in the syringe 2 enters between the needle tube 3 and the elastic member 7 and leaks to the first member 6 side of the needle hub 4. To prevent.
  • the first flange portion 72 is formed in a ring shape that protrudes radially outward from the outer peripheral surface of the main body portion 70.
  • the outer diameter of the first flange portion 72 is substantially equal to the outer diameter of the base portion 9 of the first member 6.
  • the elastic member 7 is attached to the needle hub 4 by holding the first flange portion 72 between the engaging portion 24 of the second member 8 and the base portion 9 of the first member 6.
  • the second flange portion 73 is formed in a ring shape that protrudes radially outward from the outer peripheral surface of the main body portion 70, similarly to the first flange portion 72.
  • the second flange portion 73 engages with the engagement surface 24 b of the engagement portion 24 provided on the second member 8.
  • the elastic member 7 is locked to move in the axial direction by the first flange portion 72 and the second flange portion 73 engaging the engaging portion 24 of the second member 8. Thereby, it can prevent that a chemical
  • Examples of the material of the elastic member 7 include various rubber materials such as synthetic rubber, natural rubber, silicone rubber, and isobutylene rubber, various thermoplastic elastomers such as polyurethane and styrene, or mixtures thereof. .
  • the syringe 2 includes a syringe body 41 and a discharge portion 42 that is continuous with the syringe body 41.
  • the syringe body 41 is formed of a circular cylinder.
  • the discharge part 42 protrudes from one end of the syringe body 41 in the axial direction, and is composed of a circular cylinder having an outer diameter smaller than that of the syringe body 41.
  • the discharge portion 42 is formed in a tapered shape whose diameter continuously decreases toward the tip.
  • the end surface 42 a that is the tip of the discharge portion 42 abuts against a stopper 23 provided on the inner wall surface of the second member 8, thereby limiting the insertion depth of the syringe 2 with respect to the needle hub 4.
  • a gap is provided between the end face 42 a and the proximal end 3 ⁇ / b> B of the needle tube 3 in the axial direction of the needle tube 3.
  • the insertion depth of the syringe 2 may be limited by the end surface 41 a of the syringe main body 41 coming into contact with the distal end of the insertion portion 20 of the second member 8, and the end surface 42 a and the needle tube 3 may be limited.
  • Other configurations may be used as long as a predetermined gap is provided between the base ends 3B.
  • the outer peripheral surface of the discharge portion 42 is provided with a screw portion 43 for screwing onto the second member 8 of the needle hub 4 and a syringe-side display portion 44.
  • the syringe-side display unit 44 is recognized via the second member 8 of the needle hub 4 when the discharge unit 42 is inserted into the insertion unit 20 provided in the needle hub 4. And when the discharge part 42 contacts the engaging part 24 of the insertion part 20 and the insertion is completed, the syringe side display part 44 coincides with the hub side display part 25 of the needle hub 4 in the circumferential direction.
  • a gasket (not shown) is accommodated in the syringe body 41.
  • the space in the syringe body 41 is liquid-tightly partitioned by a gasket, and one space communicating with the discharge part 42 forms a liquid chamber 46 together with the space in the discharge part 42.
  • a plunger (not shown) is arranged in the other space in the syringe body 41. The plunger is connected to the gasket and protrudes from the opening at the other end of the syringe body 41. By operating this plunger, the gasket is moved in the axial direction in the syringe body 41, and the medicine filled in the syringe body 41 is discharged.
  • the syringe 2 is vented after the medicine (chemical solution) 80 is filled, and the internal air is discharged in advance.
  • an amount of medicine 80 slightly larger than the volume of the syringe 2 is injected into the syringe 2, and a droplet 81 is formed at the discharge port 42 b. It is desirable to keep it.
  • synthetic resins such as polycarbonate, polypropylene, and polyethylene can be used, and glass or the like may be used.
  • a gap is provided between the proximal end 3B of the needle tube 3 and the end surface 42a of the discharge portion 42 of the syringe 2.
  • a discharge port 42 b is opened in the discharge part 42 of the syringe 2, and the syringe 2 is inserted into the insertion part 20 in a state where the internal space communicates with the internal space of the insertion part 20.
  • FIG. 3 is a cross-sectional view of the drug injection device 100 of the present embodiment provided with the syringe 2, the needle hub 4, and the cap 5 assembled.
  • the cap 5 includes a first tube portion 51 provided with a tube hole 51a, a second tube portion 52 provided with a tube hole 52a that is continuous with the first tube portion 51 and communicates with the tube hole 51a, and a second tube. And a bottom portion 53 provided with a recess 53a that is continuous with the portion 52 and communicates with the cylindrical hole 52a.
  • the first tube portion 51 has, for example, a cylindrical shape, and an opening for inserting the needle hub 4 is formed in the cap 5.
  • the diameter of the cylinder hole 51a of the first cylinder part 51 is configured to be larger than the diameter of the guide part 12, and the needle hub 4 is inserted from the cylinder hole 51a.
  • the 2nd cylinder part 52 is formed following the 1st cylinder part 51, and the axis
  • the diameter of the cylindrical hole 52a is substantially equal to the diameter of the guide portion 12, and is smaller than the diameter of the cylindrical hole 51a.
  • the diameter of the cylindrical hole 52a is defined by the protruding portion 52c protruding from the inner surface 52b of the second cylindrical portion 52.
  • the guide portion 12 of the needle hub 4 is fitted to the second cylindrical portion 52, and the needle hub 4 is fixed to the cap 5.
  • the wall surface of the protrusion 52c that forms the cylindrical hole 52a may be formed in a tapered shape in which the diameter of the cylindrical hole 52a decreases toward the bottom 53 side.
  • the bottom portion 53 is formed continuously with the second cylinder portion 52.
  • the recess 53a of the bottom 53 is formed in a circular shape, and the axis of the recess 53a coincides with the axis of the cylinder hole 52a. Further, the diameter of the concave portion 53a is substantially equal to the diameter of the stable portion 11 and is smaller than the diameter of the cylindrical hole 52a.
  • the bottom 53 is formed with a protruding portion 53c that protrudes from an inner surface 53b continuous from the inner surface 52b of the second cylindrical portion 52 or the wall surface (cylinder hole 52a) of the protruding portion 52c.
  • the diameter of the recess 53a is defined by the protrusion 53c.
  • the stable portion 11 of the first member 6 is fitted into the recess 53 a, and the needle hub 4 is fixed to the cap 5.
  • the concave portion 53a may be formed in a tapered shape having a diameter that decreases toward the bulging portion 54 described later.
  • a bulging portion 54 that bulges inside the cap 5 is formed at the center of the recess 53a.
  • the bulging portion 54 is provided with a collecting portion 55 for collecting the medicine 80 leaking from the tip 3A of the needle tube 3.
  • the collection part 55 is constituted by a protrusion protruding from the bulging part 54 and is formed in a cylindrical shape having a cylindrical hole 55a. The medicine 80 leaked from the tip 3A of the needle tube 3 is collected by the collection unit 55.
  • the collection unit 55 will be described below.
  • the syringe 2 pre-filled with the medicine 80 is vented, and then the syringe 2 is housed in the cap 5 and the needle tip 3A is moved downward.
  • the needle hub 4 is attached to the needle hub 4 in the state of facing.
  • medical agent 80 is formed in the discharge port 42b of the syringe 2.
  • FIG. Even if the air is not vented, the droplet 81 may be formed due to the weight of the medicine 80.
  • FIG. 4 shows a drug injection device 110 configured to bring the discharge portion 42 of the syringe 2 into contact with the elastic member 7 with respect to the drug injection device 100 according to the present embodiment as a comparative example.
  • parts corresponding to those of the drug injection device 100 (FIG. 2) according to the present embodiment are denoted by the same reference numerals as those in FIG.
  • no stopper is provided on the wall surface of the cylindrical hole 20 a in the insertion portion 20 of the second member 8.
  • the discharge part 42 of the syringe 2 inserted into the insertion part 20 is in contact with the elastic member 7, and is in liquid-tight contact with the end surface 70 b of the elastic member 7 at the end surface 42 a of the discharge part 42.
  • the rest is the same as the drug injection device 100 shown in FIG.
  • the droplet 81 formed on the discharge part 42 of the syringe 2 has been in contact with the proximal end 3 ⁇ / b> B of the needle tube 3.
  • the medicine 80 in the syringe 2 enters the inside of the needle tube 3 by capillary action.
  • the medicine 80 may slightly leak from the needle tip 3A of the needle tube 3 and a droplet 82 may be formed.
  • the discharge portion 42 is made fluid-tight to the fitting portion 20 by bringing the outer wall surface of the discharge portion 42 into surface contact with the inner wall surface of the cylindrical hole 20 a. It is inserted. Therefore, when the discharge portion 42 is fitted, the internal space of the cylindrical hole 20a between the end surface 42a of the discharge portion 42 and the end surface 70a of the elastic member 7 is airtight to some extent.
  • a collecting portion 55 for collecting the medicine 80 leaking from the needle tube 3 is provided on the inner wall surface of the cap 5. For this reason, even if the droplet 81 comes into contact with the proximal end 3B of the needle tube 3, when the cap 5 is removed from the needle hub 4, a droplet of the medicine 80 is not formed on the distal end 3A of the needle tube 3. Accordingly, it is possible to prevent the medicine 80 from adhering to the surroundings or injecting the patient into the patient while the liquid droplet is attached to the needle tube 3.
  • the medicine 80 leaks from the needle tip 3A by using the syringe 2 filled with the medicine 80 and previously vented, a droplet is dropped on the needle tip 3A. Is not formed. For this reason, the syringe 2 filled with the medicine 80 and evacuated can be attached in advance to the injection needle assembly 1, and the work of discharging the air in the syringe after being attached to the needle hub is possible. unnecessary.
  • the medicine injection is performed so that the end surface 42a of the discharge portion 42 of the syringe 2 contacts the end surface 70b of the elastic member 7. It is also possible to configure the device 100.
  • the collection unit 55 is configured by a protrusion protruding from the inner wall surface of the cap 5. Further, this protrusion is arranged in the vicinity of the needle tip 3 ⁇ / b> A of the needle tube 3.
  • the droplet comes into contact with the recovery unit 55 disposed in the vicinity of the needle tip 3 ⁇ / b> A of the needle tube 3.
  • the liquid droplet that has contacted the collection unit 55 travels along the wall surface of the collection unit 55 due to its own weight or the like, or is transferred to the bottom of the cylindrical hole 55a of the collection unit 55 and moved to be accumulated in the cylindrical hole 55a.
  • the medicine 80 for example, a liquid having a smaller surface tension such as a vaccine, the liquid droplet can be easily moved from the needle tip 3A to the collection unit 55.
  • the distance between the collection portion 55 and the needle tip 3A is preferably 0.5 mm or more and 3 mm or less.
  • the liquid droplets are attached to the wall surface of the collection unit 55, at least a part of the needle tip 3A of the needle tube 3 is located in the cylindrical hole 55a of the collection unit 55. That is, it is desirable that the needle tube 3 and the collection unit 55 intersect in the axial direction of the needle tube 3.
  • the surface of the collection unit 55 is more than the needle tube 3 with respect to the medicine 80.
  • High wettability is preferred.
  • the recovery part 55 may be molded integrally with the bottom part 53.
  • the collection unit 55 may be formed by attaching another member made of a material having higher wettability than the needle tube 3 to the medicine 80. Further, the wettability of the collection unit 55 may be improved by surface treatment such as plasma discharge or ultraviolet irradiation.
  • the configuration is such that a liquid drop formed on the needle tip 3A is collected by providing a cylindrical projection on the bottom 53 of the cap 5, but the liquid drop may be attached to the cap 5 side.
  • other configurations may be used.
  • a protrusion close to the axial direction of the needle tube 3 may be provided, and the droplet may be attached to the protrusion by moving the droplet in the axial direction of the needle tube 3.
  • the protrusion You may make it make it make a droplet adhere to.
  • the collecting portion 55 is formed in a cylindrical shape and the needle tip 3A is disposed in the cylindrical hole 55a as in the present embodiment, the collected liquid droplets can be retained in the cylindrical hole 55a. it can.
  • the diameter of the cylinder hole 55a is small, it may be difficult to insert the needle tip 3A into the cylinder hole 55a without making contact with the inner surface of the collection part 55 that forms the cylinder hole 55a.
  • the shortest distance from the inner surface of the collection unit 55 to the inner surface of the collection unit 55 may be within the above-described distance. That is, the needle tip 3A does not have to be located on the central axis of the cylindrical hole 55a, and at least one point of the collecting portion 55 only needs to be within the above-mentioned distance from the needle tip 3A.
  • FIG. 5 is a cross-sectional view showing a configuration of the medicine injection device 200 according to the present embodiment. Parts that can have the same configuration as that of the medicine injection device 100 (see FIG. 3) according to the first embodiment are denoted by the same reference numerals as those in FIG.
  • the drug injection device 200 includes a needle tip 3A that is punctured into the skin, a needle tube 3 having a proximal end 3B opposite to the needle tip 3A, a needle hub 4 that holds the needle tube 3, and a needle hub 4 And a syringe 2 filled with a medicine 80 inside. Further, for example, a cap 5 a that is fitted to the needle hub 4 and covers the needle tip 3 A of the needle tube 3 is provided.
  • the injection needle assembly 1 ⁇ / b> A includes the needle tube 3, the needle hub 4, and the cap 5.
  • the same syringe 2, needle tube 3, and needle hub 4 as those in the first embodiment are used. Therefore, the syringe 2 is pre-bleeded after the medicine 80 is filled therein. For this reason, the droplet 81 by the chemical
  • the cap 5a includes a first tube portion 51 provided with a tube hole 51a, a second tube portion 52 provided with a tube hole 52a that is continuous with the first tube portion 51 and communicates with the tube hole 51a, and a second tube. And a bottom portion 53 provided with a recess 53a that is continuous with the portion 52 and communicates with the cylindrical hole 52a. These configurations are also the same as in the first embodiment, and the bulging portion 54 of the bottom portion 53 is provided with a collecting portion 55A for collecting the droplets formed on the needle tip 3A of the needle tube 3.
  • the recovery unit 55A includes, for example, a cylindrical protrusion 56 having a cylindrical hole 56a, and a soft material 57 that is disposed inside the cylindrical hole 56a and can puncture the needle tip 3A of the needle tube 3.
  • a soft material 57 for example, an absorbent body that absorbs the medicine 80 such as foamed polyurethane and polyacrylamide gel can be used.
  • the distance from the needle tube 3 to the projection 56 may be arbitrarily set in the surface direction perpendicular to the axis of the needle tube 3. If the distance from the needle tip 3A to the soft material 57 is 0.5 mm or more and 3 mm or less in the axial direction of the needle tube 3, the needle tip 3A is formed on the needle tip 3A without puncturing the soft material 57.
  • the liquid droplets can be brought into contact with the soft material 57 and absorbed by the soft material 57.

Abstract

The invention provides an injection needle assembly to which a syringe from which air has been evacuated can be attached, and a drug injection device using the injection needle assembly. This injection needle assembly (1) is equipped with: a needle tube (3) having a needle point (3A) that pierces the skin and a base end (3B) on the end opposite the needle point (3A); a needle hub (4) having an insertion part (20) into which an outlet (42) of a syringe (2) is inserted, the syringe having a drug (80) filled therein, the outlet (42) for discharging the drug (80) and the air evacuated from within, and a holding part, which holds the needle tube (3) and positions the base end of the needle tube (3) in the insertion part (20); and a cap (5), which is provided on the inner wall surface with a recovery part (55) for recovering liquid drops (81) that have leaked out from the needle point (3A). The drug injection device (100) is configured by attaching a syringe (2), which is filled with the drug (80) and from which air has been evacuated, to the injection needle assembly (1).

Description

注射針組立体及び薬剤注射装置Injection needle assembly and drug injection device
 本発明は、薬剤が内部に収容され、エア抜きが行われたシリンジを取り付けておくことができる注射針組立体、及び薬剤注射装置に関する。 The present invention relates to an injection needle assembly and a drug injection device in which a syringe in which a drug is contained and an air vent is performed can be attached.
 近年、シリンジ内に予め薬剤が充填されたプレフィルドシリンジが多く利用されるようになってきている。こうしたプレフィルドシリンジでは、薬剤投与時にバイアルからシリンジ内に薬剤を吸引する作業を必要としないため、薬剤の投与に要する時間を短縮することが可能である。 In recent years, prefilled syringes in which a medicine is prefilled in a syringe are often used. Such a prefilled syringe does not require an operation of sucking the drug from the vial into the syringe at the time of drug administration, and thus it is possible to reduce the time required for drug administration.
 例えば、下記特許文献1では、薬剤が充填されたシリンジ本体と、シリンジ本体に装着され、薬剤をシリンジ本体内に封止するキャップとを備えるプレフィルドシリンジが開示されている。 For example, the following Patent Document 1 discloses a prefilled syringe including a syringe body filled with a medicine and a cap attached to the syringe body and sealing the medicine in the syringe body.
 こうしたプレフィルドシリンジを使用する際には、注射針が固定された針ハブをプレフィルドシリンジの先端である薬剤の排出部に取り付け、注射針の基端をシリンジ本体内部に連通させる。そして、シリンジ本体に設けられた押し子を押圧することにより、注射針の針先から薬剤が排出される。 When using such a prefilled syringe, a needle hub to which the injection needle is fixed is attached to the medicine discharge portion which is the tip of the prefilled syringe, and the proximal end of the injection needle is communicated with the inside of the syringe body. And a chemical | medical agent is discharged | emitted from the needle point of an injection needle by pressing the pusher provided in the syringe main body.
 プレフィルドシリンジを用いた注射器では、上述のように、バイアルから薬剤を吸引する必要が無いため、薬剤の投与に要する時間を短縮することが可能である。
 しかし、投与するには、薬剤が充填されたシリンジを別に準備した針ハブに取り付ける作業と、シリンジ内の空気を排出する、いわゆるエア抜きを行う作業が必要である。
In the syringe using the prefilled syringe, as described above, it is not necessary to suck the drug from the vial, so that it is possible to reduce the time required for the drug administration.
However, in order to administer, the operation | work which attaches the syringe filled with the chemical | medical agent to the needle hub prepared separately, and the operation | work which performs what is called air bleeding which discharges | emits the air in a syringe are required.
 また、下記特許文献2に開示されている注射針組立体では、安定した穿刺を行うために、注射針を穿刺する深さを調整することができる皮膚接触部が設けられている。この注射針組立体において、シリンジを針ハブに取り付けた後にエア抜きを行うと、注射針の先端から液滴が漏洩し、皮膚接触部や、皮膚接触部と針管との間に薬品が付着する恐れがある。このため、シリンジを針ハブに取り付ける前にシリンジのエア抜きを行うことも考えられる。 In addition, in the injection needle assembly disclosed in Patent Document 2 below, a skin contact portion capable of adjusting the depth of puncture of the injection needle is provided in order to perform stable puncture. In this injection needle assembly, if the air is vented after the syringe is attached to the needle hub, the liquid droplet leaks from the tip of the injection needle, and the chemical adheres between the skin contact portion and the skin contact portion and the needle tube. There is a fear. For this reason, it is also conceivable to vent the syringe before attaching the syringe to the needle hub.
特開2004-321826号公報JP 2004-321826 A 特開2000-037456号公報JP 2000-037456 A
 しかし、シリンジを針ハブに取り付ける前にシリンジのエア抜きを行っても、エア抜きを行ったシリンジを針ハブに取り付ける時に、シリンジの排出部に溜まっている薬剤が注射針を通じて、その先端から排出される場合がある。 However, even if the syringe is bleed before the syringe is attached to the needle hub, when the evacuated syringe is attached to the needle hub, the drug accumulated in the syringe discharge part is discharged from the tip through the injection needle. May be.
 本発明は上述の点に鑑み、エア抜きを行ったシリンジを取り付け可能な注射針組立体、及びその注射針組立体を用いた薬剤注射装置を提供することを目的とする。 The present invention has been made in view of the above points, and an object of the present invention is to provide an injection needle assembly to which a syringe that has been evacuated can be attached, and a medicine injection device using the injection needle assembly.
 上記課題を解決するために、本発明による注射針組立体は、皮膚に穿刺される針先と、針先と反対側の基端を有する針管を備える。また、内部に充填された薬剤と、この薬剤を排出する排出部とを有し、内部から空気が排出された状態のシリンジの排出部が嵌入される嵌入部と、針管を保持して針管の基端を嵌入部に位置させる保持部と、を有する針ハブを備える。また、針管の針先を覆うキャップを備える。そして、このキャップの内壁面には、針先から漏れ出た液滴を回収する回収部が設けられている。 In order to solve the above problems, an injection needle assembly according to the present invention includes a needle tip that is pierced into the skin and a needle tube having a proximal end opposite to the needle tip. Also, it has a medicine filled inside and a discharge part for discharging the medicine, a fitting part into which a discharge part of a syringe in a state where air is discharged from the inside is inserted, a needle tube holding the needle tube, A needle hub having a holding portion for positioning the proximal end at the fitting portion. Moreover, the cap which covers the needle tip of a needle tube is provided. The inner wall surface of the cap is provided with a collection unit that collects liquid droplets leaking from the needle tip.
 また、本発明による薬剤注射装置は、上述の注射針組立体にシリンジを取り付けたものである。このシリンジは、内部に充填された薬剤と、この薬剤を排出する排出部とを有し、内部から空気が排出されている。 The drug injection device according to the present invention is a device in which a syringe is attached to the above-described injection needle assembly. This syringe has a medicine filled inside and a discharge part for discharging the medicine, and air is discharged from the inside.
 本発明の注射針組立体及び薬剤注射装置によれば、キャップの内壁面に、針先から漏れ出た液滴を回収する回収部が設けられている。このため、内部に薬剤を充填し、空気を排出したシリンジを取り付けても、針管の針先に液滴が形成されるのを抑制することができる。 According to the injection needle assembly and the drug injection device of the present invention, the recovery unit that recovers the liquid droplet leaking from the needle tip is provided on the inner wall surface of the cap. For this reason, even if the syringe which filled the inside with the chemical | medical agent and discharged | emitted air is attached, it can suppress that a droplet is formed in the needle tip of a needle tube.
 本発明の注射針組立体及び薬剤注射装置によれば、針管の針先に液滴が形成されるのを抑制できるので、内部に薬剤を充填し、空気を排出したシリンジを予め取り付けておくことが可能となる。このため、針ハブに取り付けた後にシリンジ内の空気を排出する作業を軽減でき、また周囲に薬品を付着させるのを抑制できる。 According to the injection needle assembly and the drug injection device of the present invention, it is possible to suppress the formation of liquid droplets at the needle tip of the needle tube, so that a syringe filled with the drug and exhausted air is attached in advance. Is possible. For this reason, the operation | work which discharges the air in a syringe after attaching to a needle hub can be reduced, and it can suppress that a chemical | medical agent adheres to the circumference | surroundings.
本発明の第1の実施の形態に係る薬剤注射装置の構成を示す分解図である。It is an exploded view showing the composition of the medicine injection device concerning a 1st embodiment of the present invention. 本発明の第1の実施の形態に係る薬剤注射装置の構成を示す断面図である。It is sectional drawing which shows the structure of the chemical injection device which concerns on the 1st Embodiment of this invention. 本発明の第1の実施の形態に係る薬剤注射装置の構成を示す断面図である。It is sectional drawing which shows the structure of the chemical injection device which concerns on the 1st Embodiment of this invention. 針管の針先から薬剤が漏れ出る状態を示す説明図である。It is explanatory drawing which shows the state which a chemical | medical agent leaks from the needle point of a needle tube. 本発明の第2の実施の形態に係る薬剤注射装置の構成を示す断面図である。It is sectional drawing which shows the structure of the chemical injection apparatus which concerns on the 2nd Embodiment of this invention.
 以下本発明を実施するための形態の例を説明するが、本発明は以下の例に限定されるものではない。説明は以下の順序で行う。
1.第1の実施の形態(筒状の突起を設ける例)
2.第2の実施の形態(軟材を配置し、軟材内部に針管の針先を埋設する例)
Examples of modes for carrying out the present invention will be described below, but the present invention is not limited to the following examples. The description will be made in the following order.
1. 1st Embodiment (example which provides a cylindrical protrusion)
2. Second Embodiment (Example in which soft material is arranged and the needle tip of a needle tube is embedded in the soft material)
1.第1の実施の形態
 図1は、本実施の形態に係る薬剤注射装置100の分解図である。
 薬剤注射装置100は、針先を皮膚の表面より穿刺し、例えば皮膚上層部に薬剤を注入する場合に用いる。図1に示すように、この薬剤注射装置100は、注射針組立体1と、この注射針組立体1に接続され、薬剤(薬液)が充填されたシリンジ2とから構成されている。
1. First Embodiment FIG. 1 is an exploded view of a medicine injection device 100 according to the present embodiment.
The drug injection device 100 is used when the needle tip is punctured from the surface of the skin and, for example, the drug is injected into the upper layer of the skin. As shown in FIG. 1, the drug injection device 100 includes an injection needle assembly 1 and a syringe 2 connected to the injection needle assembly 1 and filled with a drug (medicine solution).
[注射針組立体]
 注射針組立体1は、針孔を有する中空の針管3と、この針管3が固定される針ハブ4と、針ハブ4内に配置される弾性部材7と、針ハブ4に着脱可能に取り付けられ、針管3を保護するキャップ5を備えている。そして、針ハブ4は、針管3を保持する第1部材6と、シリンジ2の後述する排出部42が嵌入される第2部材8からなっている。
[Injection needle assembly]
The injection needle assembly 1 includes a hollow needle tube 3 having a needle hole, a needle hub 4 to which the needle tube 3 is fixed, an elastic member 7 disposed in the needle hub 4, and a detachable attachment to the needle hub 4. And a cap 5 for protecting the needle tube 3. The needle hub 4 includes a first member 6 that holds the needle tube 3 and a second member 8 into which a later-described discharge portion 42 of the syringe 2 is inserted.
 注射針組立体1の針管3は、ISOの医療用針管の基準(ISO9626:1991/Amd.1:2001(E))で26~33ゲージのサイズ(外径0.2~0.45mm)のものを使用し、好ましくは30~33ゲージのものを使用する。 The needle tube 3 of the injection needle assembly 1 has a size of 26 to 33 gauge (outer diameter 0.2 to 0.45 mm) according to the ISO medical needle tube standard (ISO9626: 1991 / Amd.1: 2001 (E)). Those of 30 to 33 gauge are preferably used.
 図2は、シリンジ2と針管3と針ハブ4とが組み付けられた状態を示す断面図である。
 図2に示すように、針管3の一端には、刃面3aを有する針先3Aが設けられている。以下、針先3Aとは反対側である針管3の他端を「基端3B」という。刃面3aにおける針管3の軸方向の長さ(以下、「ベベル長」という)は、後述する皮膚上層部の最薄の厚さである1.4mm(成人)以下であればよく、また、33ゲージの針管に短ベベルを形成したときのベベル長である約0.5mm以上であればよい。つまり、ベベル長は、0.5~1.4mmの範囲に設定されるのが好ましい。
FIG. 2 is a cross-sectional view showing a state in which the syringe 2, the needle tube 3, and the needle hub 4 are assembled.
As shown in FIG. 2, a needle tip 3 </ b> A having a blade surface 3 a is provided at one end of the needle tube 3. Hereinafter, the other end of the needle tube 3 opposite to the needle tip 3A is referred to as a “base end 3B”. The axial length of the needle tube 3 on the blade surface 3a (hereinafter referred to as “bevel length”) may be 1.4 mm (adult) or less, which is the thinnest thickness of the upper skin portion described later, What is necessary is just about 0.5 mm or more which is the bevel length when a short bevel is formed in a 33 gauge needle tube. That is, the bevel length is preferably set in the range of 0.5 to 1.4 mm.
 さらに、ベベル長は、皮膚上層部の最薄の厚さが0.9mm(小児)以下、すなわち、ベベル長が0.5~0.9mmの範囲であればなおよい。なお、短ベベルとは、注射用針に一般的に用いられる、針の長手方向に対して18~25°をなす刃面を指す。 Further, the bevel length is further preferably such that the thinnest thickness of the upper skin layer is 0.9 mm (child) or less, that is, the bevel length is in the range of 0.5 to 0.9 mm. The short bevel refers to a blade surface that is generally used for injection needles and forms an angle of 18 to 25 ° with respect to the longitudinal direction of the needle.
 針管3の材料としては、例えば、ステンレス鋼を挙げることができるが、これに限定されるものではなく、アルミニウム、アルミニウム合金、チタン、チタン合金その他の金属を用いることができる。
 また、針管3は、ストレート針だけでなく、少なくとも一部がテーパー状となっているテーパー針を用いることができる。テーパー針としては、針先端部に比べて基端が大きい径を有しており、その中間部分をテーパー構造とすればよい。また、針管3の断面形状は、円形だけでなく、三角形等の多角形であってもよい。
Examples of the material of the needle tube 3 include stainless steel, but are not limited thereto, and aluminum, aluminum alloy, titanium, titanium alloy, and other metals can be used.
Further, the needle tube 3 can be not only a straight needle but also a tapered needle having at least a part tapered. As the tapered needle, the proximal end has a larger diameter than the needle distal end, and the intermediate portion may have a tapered structure. Further, the cross-sectional shape of the needle tube 3 may be not only a circle but also a polygon such as a triangle.
 次に、針ハブ4について説明する。
 針ハブ4の第1部材6と第2部材8は、別部材として形成されているが、一体に形成することもできる。これら第1部材6及び第2部材8の材質としては、例えばポリカーボネート、ポリプロピレン、ポリエチレン等の合成樹脂を挙げることができる。
Next, the needle hub 4 will be described.
The first member 6 and the second member 8 of the needle hub 4 are formed as separate members, but may be formed integrally. Examples of the material of the first member 6 and the second member 8 include synthetic resins such as polycarbonate, polypropylene, and polyethylene.
 第1部材6は、ベース部9と、調整部10と、安定部11と、ガイド部12を備えている。第1部材6は、針管3を保持する保持部として構成される。ベース部9は、略円柱状に形成されており、軸方向に垂直な端面9a,9bを有している。調整部10は、ベース部9の端面9aの中央部に設けられており、ベース部9の軸方向に突出する円柱状の凸部からなっている。この調整部10の軸心は、ベース部9の軸心に一致している。 The first member 6 includes a base portion 9, an adjustment portion 10, a stabilization portion 11, and a guide portion 12. The first member 6 is configured as a holding unit that holds the needle tube 3. The base portion 9 is formed in a substantially cylindrical shape and has end faces 9a and 9b perpendicular to the axial direction. The adjustment unit 10 is provided at the center of the end surface 9 a of the base unit 9, and includes a columnar projection that protrudes in the axial direction of the base unit 9. The axis of the adjustment unit 10 is coincident with the axis of the base unit 9.
 ベース部9及び調整部10の軸心には、針管3が貫通する貫通孔13が設けられている。そして、ベース部9には、貫通孔13に接着剤14を注入するための注入用孔15が設けられている。この注入用孔15は、ベース部9の外周面に開口されており、貫通孔13に連通している。すなわち、注入用孔15から貫通孔13へ注入された接着剤14により、針管3がベース部9に固着される。 A through hole 13 through which the needle tube 3 passes is provided in the axial center of the base portion 9 and the adjustment portion 10. The base portion 9 is provided with an injection hole 15 for injecting the adhesive 14 into the through hole 13. The injection hole 15 is opened on the outer peripheral surface of the base portion 9 and communicates with the through hole 13. That is, the needle tube 3 is fixed to the base portion 9 by the adhesive 14 injected from the injection hole 15 to the through hole 13.
 針管3の基端3B側は、ベース部9の端面9bから突出している。ベース部9は、端面9b側から第2部材8内に挿入され、針管3の基端3B側が弾性部材7の後述する挿通孔71に挿通される。そして、ベース部9の端面9bが弾性部材7の後述する端面70aに当接される。 The proximal end 3B side of the needle tube 3 protrudes from the end surface 9b of the base portion 9. The base portion 9 is inserted into the second member 8 from the end surface 9b side, and the proximal end 3B side of the needle tube 3 is inserted into an insertion hole 71 described later of the elastic member 7. And the end surface 9b of the base part 9 is contact | abutted to the end surface 70a which the elastic member 7 mentions later.
 ベース部9の外周面には、接続片16が設けられている。この接続片16は、ベース部9の半径方向に突出するリング状のフランジとして形成されており、ベース部9の軸方向に対向する平面16a,16bを有している。接続片16の平面16bには、第2部材8が接続される。また、接続片16の先端部は、ガイド部12になっている。このガイド部12については、後で詳しく説明する。 A connecting piece 16 is provided on the outer peripheral surface of the base portion 9. The connection piece 16 is formed as a ring-shaped flange projecting in the radial direction of the base portion 9, and has flat surfaces 16 a and 16 b facing the axial direction of the base portion 9. The second member 8 is connected to the flat surface 16 b of the connection piece 16. Further, the distal end portion of the connection piece 16 is a guide portion 12. The guide portion 12 will be described in detail later.
 調整部10の端面は、針管3の針先3A側が突出する針突出面10aになっている。針突出面10aは、針管3の軸方向に直交する平面として形成されている。この針突出面10aは、針管3を皮膚上層部に穿刺するときに、皮膚の表面に接触して針管3を穿刺する深さを規定する。つまり、針管3が皮膚上層部に穿刺される深さは、針突出面10aから突出する針管3の長さ(以下、「突出長L」という。)によって決定される。 The end surface of the adjusting portion 10 is a needle protruding surface 10a from which the needle tip 3A side of the needle tube 3 protrudes. The needle projecting surface 10 a is formed as a plane orthogonal to the axial direction of the needle tube 3. The needle protruding surface 10a defines the depth of puncturing the needle tube 3 in contact with the skin surface when the needle tube 3 is punctured into the upper skin portion. That is, the depth at which the needle tube 3 is punctured into the upper skin layer is determined by the length of the needle tube 3 protruding from the needle protruding surface 10a (hereinafter referred to as “projection length L”).
 皮膚上層部の厚みは、皮膚の表面から真皮層までの深さに相当し、概ね、0.5~3.0mmの範囲内にある。そのため、針管3の突出長Lは、0.5~3.0mmの範囲に設定することができる。 The thickness of the upper skin portion corresponds to the depth from the skin surface to the dermis layer, and is generally in the range of 0.5 to 3.0 mm. Therefore, the protruding length L of the needle tube 3 can be set in the range of 0.5 to 3.0 mm.
 ところで、ワクチンは一般的に上腕部に投与されるが、皮膚上層部への投与の場合には、皮膚が厚い肩周辺部、特に三角筋部が好ましい。小児19人と大人31人について、三角筋の皮膚上層部の厚みを測定した結果によると、小児の三角筋における皮膚上層部の厚みは、0.9~1.6mmであった。また、成人の三角筋における皮膚上層部の厚みは、遠位部で1.4~2.6mm、中央部で1.4~2.5mm、近位部で1.5~2.5mmであった。以上のことから、三角筋における皮膚上層部の厚みは、小児の場合で0.9mm以上、成人の場合で1.4mm以上であることが確認された。したがって、三角筋の皮膚上層部における注射において、針管3の突出長Lは、0.9~1.4mmの範囲に設定することが好ましい。 By the way, the vaccine is generally administered to the upper arm, but in the case of administration to the upper skin part, the shoulder peripheral part where the skin is thick, particularly the deltoid part is preferable. According to the results of measuring the thickness of the upper layer of the deltoid muscle of 19 children and 31 adults, the thickness of the upper layer of the skin of the deltoid muscle of the child was 0.9 to 1.6 mm. In addition, the thickness of the upper skin layer of the deltoid muscle of adults was 1.4 to 2.6 mm at the distal part, 1.4 to 2.5 mm at the central part, and 1.5 to 2.5 mm at the proximal part. It was. From the above, it was confirmed that the thickness of the upper skin layer in the deltoid muscle was 0.9 mm or more in the case of children and 1.4 mm or more in the case of adults. Therefore, in the injection at the upper layer portion of the deltoid skin, the protruding length L of the needle tube 3 is preferably set in the range of 0.9 to 1.4 mm.
 突出長Lをこのように設定することで、針先3Aの刃面3aを皮膚上層部に確実に位置させることが可能となる。その結果、刃面3aに開口する針孔(薬剤排出口)は、刃面3a内のいかなる位置にあっても、皮膚上層部に位置することが可能である。なお、薬剤排出口が皮膚上層部に位置しても、針先3Aが皮膚上層部よりも深く刺されば、針先3A端部の側面と切開された皮膚との間から薬剤が皮下に流れてしまうため、刃面3aが確実に皮膚上層部にあることが重要である。 By setting the protruding length L in this way, the blade surface 3a of the needle tip 3A can be reliably positioned on the upper skin portion. As a result, the needle hole (medicine discharge port) that opens in the blade surface 3a can be located in the upper skin layer portion at any position within the blade surface 3a. Even if the medicine discharge port is located in the upper skin layer, if the needle tip 3A is stabbed deeper than the upper skin layer, the medicine flows subcutaneously between the side surface of the end of the needle tip 3A and the cut skin. Therefore, it is important that the blade surface 3a is surely in the upper skin portion.
 なお、26ゲージよりも太い針管では、ベベル長を1.0mm以下にすることは難しい。したがって、針管3の突出長Lを好ましい範囲(0.9~1.4mm)に設定するには、26ゲージよりも細い針管を使用することが好ましい。 Note that it is difficult to make the bevel length 1.0 mm or less with a needle tube thicker than 26 gauge. Therefore, in order to set the protruding length L of the needle tube 3 within a preferable range (0.9 to 1.4 mm), it is preferable to use a needle tube thinner than 26 gauge.
 針突出面10aは、周縁から針管3の外周面までの距離Sが1.4mm以下となるように形成し、好ましくは0.3~1.4mmの範囲で形成する。この針突出面10aの周縁から針管3の周面までの距離Sは、皮膚上層部へ薬剤を投与することで形成される水疱に圧力が加わることを考慮して設定している。つまり、針突出面10aは、皮膚上層部に形成される水疱よりも十分に小さく、水疱の形成を妨げない大きさに設定している。その結果、針突出面10aが針管3の周囲の皮膚を押圧しても、投与された薬剤が漏れることを防止することができる。 The needle projecting surface 10a is formed such that the distance S from the peripheral edge to the outer peripheral surface of the needle tube 3 is 1.4 mm or less, preferably in the range of 0.3 to 1.4 mm. The distance S from the peripheral edge of the needle protruding surface 10a to the peripheral surface of the needle tube 3 is set in consideration of the pressure applied to the blisters formed by administering the drug to the upper skin layer. That is, the needle protruding surface 10a is set to a size that is sufficiently smaller than the blisters formed in the upper skin layer and does not hinder the formation of blisters. As a result, even if the needle protruding surface 10a presses the skin around the needle tube 3, it is possible to prevent the administered medicine from leaking.
 安定部11は、ベース部9に設けた接続片16の平面16aから突出する筒状に形成されている。安定部11の筒孔には、針管3及び調整部10が配置されている。つまり、安定部11は、針管3が貫通する調整部10の周囲を覆う筒状に形成されており、針管3の針先3Aから半径方向に離間して設けられている。 The stabilizing part 11 is formed in a cylindrical shape protruding from the flat surface 16 a of the connecting piece 16 provided on the base part 9. The needle tube 3 and the adjustment unit 10 are disposed in the cylindrical hole of the stabilization unit 11. That is, the stabilizing portion 11 is formed in a cylindrical shape that covers the periphery of the adjusting portion 10 through which the needle tube 3 passes, and is provided away from the needle tip 3A of the needle tube 3 in the radial direction.
 図2に示すように、安定部11の端面11aは、調整部10の針突出面10aよりも針管3の基端3B側に位置している。針管3の針先3Aを生体に穿刺すると、まず、針突出面10aが皮膚の表面に接触し、その後、安定部11の端面11aに接触する。このとき、安定部11の端面11aが皮膚に接触することで薬剤注射装置100が安定し、針管3を皮膚に対して略垂直な姿勢に保つことができる。 2, the end surface 11a of the stabilizing portion 11 is located closer to the proximal end 3B side of the needle tube 3 than the needle protruding surface 10a of the adjusting portion 10. When the living body is punctured with the needle tip 3 </ b> A of the needle tube 3, first, the needle protruding surface 10 a contacts the surface of the skin, and then contacts the end surface 11 a of the stabilizing portion 11. At this time, the drug injection device 100 is stabilized by the end surface 11a of the stabilizing portion 11 coming into contact with the skin, and the needle tube 3 can be maintained in a posture substantially perpendicular to the skin.
 また、安定部11には、その外周面から内周面にかけて貫通する第1の通気孔17が形成されている。この第1の通気孔17を安定部11に設けることにより、安定部11を皮膚に接触させた際に、安定部11と皮膚とで囲まれた空間と、安定部11の外側の空間とを連通させることができる。
 調整部10にも、その側面を貫き、貫通孔13に連通した第2の通気孔18が設けられている。第1の通気孔17と第2の通気孔18は、安定部11と皮膚とで囲まれた空間と、貫通孔13を外部に開放する通気手段を構成している。
The stabilizing portion 11 is formed with a first vent hole 17 penetrating from the outer peripheral surface to the inner peripheral surface. By providing the first ventilation hole 17 in the stable portion 11, when the stable portion 11 is brought into contact with the skin, a space surrounded by the stable portion 11 and the skin and a space outside the stable portion 11 are separated. Can communicate.
The adjustment portion 10 is also provided with a second ventilation hole 18 that penetrates the side surface thereof and communicates with the through hole 13. The first ventilation hole 17 and the second ventilation hole 18 constitute a space surrounded by the stabilizing portion 11 and the skin and a ventilation means for opening the through hole 13 to the outside.
 なお、安定部11の端面11aは、針突出面10aと同一平面上に位置させたり、また、針突出面10aよりも針管3の針先3A側に位置させたりしても、針管3を皮膚に対して略垂直な姿勢に保つことができる。なお、安定部11を皮膚に押し付けた際の皮膚の盛り上がりを考慮すると、安定部11の端面11aと針突出面10aにおける軸方向の距離は、1.3mm以下に設定することが好ましい。 Even if the end surface 11a of the stabilizing portion 11 is located on the same plane as the needle projecting surface 10a, or is located closer to the needle tip 3A side of the needle tube 3 than the needle projecting surface 10a, the needle tube 3 is skinned. It is possible to keep the posture substantially perpendicular to the angle. In consideration of the swelling of the skin when the stable portion 11 is pressed against the skin, the axial distance between the end surface 11a of the stable portion 11 and the needle protruding surface 10a is preferably set to 1.3 mm or less.
 また、安定部11の内径dは、皮膚に形成される水疱の直径と同等であるか、それよりも大きい値に設定されている。具体的には、安定部11の内壁面から針突出面10aの周縁までの距離Tが4mm~15mmの範囲となるように設定されている。これにより、安定部11の内壁面から水疱に圧力が印加されことによって水疱形成が阻害されることを防止することができる。 Further, the inner diameter d of the stable portion 11 is set to a value equal to or larger than the diameter of the blister formed on the skin. Specifically, the distance T from the inner wall surface of the stable portion 11 to the peripheral edge of the needle protruding surface 10a is set to be in the range of 4 mm to 15 mm. Thereby, it can prevent that blister formation is inhibited by pressure being applied to the blister from the inner wall surface of the stable part 11.
 安定部11の内壁面から針突出面10aの周縁までの距離Tは、4mm以上であれば、特に上限はない。しかしながら、距離Tを大きくすると、安定部11の外径が大きくなるため、小児のように細い腕に針管3を穿刺する場合に、安定部11の端面11a全体を皮膚に接触させることが難しくなる。そのため、距離Tは、小児の腕の細さを考慮して15mmを最大と規定することが好ましい。 The distance T from the inner wall surface of the stable portion 11 to the peripheral edge of the needle protruding surface 10a is not particularly limited as long as it is 4 mm or more. However, when the distance T is increased, the outer diameter of the stable portion 11 is increased, so that it becomes difficult to bring the entire end surface 11a of the stable portion 11 into contact with the skin when the needle tube 3 is punctured into a thin arm like a child. . For this reason, the distance T is preferably set to 15 mm as a maximum in consideration of the thinness of the child's arm.
 針突出面10aの周縁から針管3の外周面までの距離Sが0.3mm以上であれば、調整部10が皮膚に進入することはない。したがって、安定部11の内壁面から針突出面10aの周縁までの距離T(4mm以上)及び針突出面10aの直径(約0.3mm)を考慮すると、安定部11の内径dは9mm以上に設定することができる。 If the distance S from the peripheral edge of the needle protruding surface 10a to the outer peripheral surface of the needle tube 3 is 0.3 mm or more, the adjusting unit 10 does not enter the skin. Therefore, considering the distance T (4 mm or more) from the inner wall surface of the stable portion 11 to the periphery of the needle protruding surface 10a and the diameter (about 0.3 mm) of the needle protruding surface 10a, the inner diameter d of the stable portion 11 is 9 mm or more. Can be set.
 なお、安定部11の形状は、円筒状に限定されるものではなく、例えば、中心に筒孔を有する四角柱や六角柱等の角筒状に形成してもよい。 In addition, the shape of the stable part 11 is not limited to a cylindrical shape, and may be formed in a rectangular tube shape such as a quadrangular column or a hexagonal column having a cylindrical hole at the center.
 ガイド部12は、接続片16における安定部11の位置よりも周縁側の部分である。このガイド部12は、皮膚と接触する接触面12aを有している。接触面12aは、接続片16における平面16aの一部であり、安定部11の端面11aと略平行をなす平面である。ガイド部12の接触面12aが皮膚に接触するまで安定部11を押し付けることにより、安定部11及び針管3が皮膚を押圧する力を常に所定値以上に確保することができる。これにより、針管3の針突出面10aから突出している部分(突出長Lに相当)が確実に皮膚内に穿刺される。 The guide portion 12 is a portion on the peripheral side with respect to the position of the stable portion 11 in the connection piece 16. The guide portion 12 has a contact surface 12a that comes into contact with the skin. The contact surface 12 a is a part of the flat surface 16 a of the connection piece 16 and is a flat surface that is substantially parallel to the end surface 11 a of the stabilizing portion 11. By pressing the stable portion 11 until the contact surface 12a of the guide portion 12 comes into contact with the skin, the force with which the stable portion 11 and the needle tube 3 press the skin can always be secured to a predetermined value or more. Thereby, the part (equivalent to the protrusion length L) which protrudes from the needle | hook protrusion surface 10a of the needle tube 3 is punctured in skin reliably.
 ガイド部12の接触面12aから安定部11の端面11aまでの距離(以下、「ガイド部高さ」という。)Yは、針管3及び安定部11が適正な押圧力で皮膚を押圧し穿刺することができるようにその長さが設定されている。これにより、針管3及び安定部11による皮膚への押圧力をガイド部12が案内し、針管3の針先3A(刃面3a)を皮膚上層部に確実に位置させることができると共に、使用者に安心感を与えることができる。なお、針管3及び安定部11の適正な押圧力は、例えば、3~20Nである。 The distance Y from the contact surface 12a of the guide portion 12 to the end surface 11a of the stable portion 11 (hereinafter referred to as “guide portion height”) Y punctures the needle tube 3 and the stable portion 11 by pressing the skin with an appropriate pressing force. Its length is set so that it can. As a result, the guide portion 12 guides the pressing force applied to the skin by the needle tube 3 and the stabilizing portion 11, and the needle tip 3A (blade surface 3a) of the needle tube 3 can be reliably positioned on the upper skin portion of the skin. Can give you a sense of security. An appropriate pressing force of the needle tube 3 and the stable portion 11 is, for example, 3 to 20N.
 ガイド部高さYは、安定部11の内径dの範囲が11~14mmの場合、ガイド部12の先端面から安定部11の外周面までの長さ(以下、「ガイド部長さ」という。)Xに基づいて適宜決定される。例えば、安定部11の内径dが12mmであり、ガイド部長さXが3.0mmのとき、ガイド部高さYは、2.3~6.6mmの範囲に設定される。 When the range of the inner diameter d of the stable portion 11 is 11 to 14 mm, the guide portion height Y is the length from the tip surface of the guide portion 12 to the outer peripheral surface of the stable portion 11 (hereinafter referred to as “guide portion length”). It is determined appropriately based on X. For example, when the inner diameter d of the stable portion 11 is 12 mm and the guide portion length X is 3.0 mm, the guide portion height Y is set in the range of 2.3 to 6.6 mm.
 ガイド部12には、キャップ5(図1参照)が着脱可能に嵌合される。このキャップ5は、針管3の針先3Aを覆う。これにより、針ハブ4をシリンジ2に装着する場合に、針先3Aが使用者の指先等に触れないようにすることができる。また、使用済みの薬剤注射装置100或いは注射針組立体1を常に安全な状態に保つことができ、使用者は、安心して使用済みの薬剤注射装置100或いは注射針組立体1の廃棄処理等を行うことができる。 The cap 5 (see FIG. 1) is detachably fitted to the guide portion 12. The cap 5 covers the needle tip 3 </ b> A of the needle tube 3. Thereby, when attaching needle hub 4 to syringe 2, needle tip 3A can be prevented from touching a user's fingertip. In addition, the used medicine injection device 100 or the needle assembly 1 can be always kept in a safe state, and the user can safely dispose of the used medicine injection device 100 or the needle assembly 1 or the like. It can be carried out.
 次に、第2部材8について説明する。第2部材8は、略筒状に形成されている。この第2部材8の軸方向の一端部は、第1部材6のベース部9を挿入する挿入部19になっており、他端部は、シリンジ2の排出部42が嵌入する嵌入部20になっている。挿入部19の筒孔19aは、第1部材6のベース部9に対応した大きさに設定されている。 Next, the second member 8 will be described. The second member 8 is formed in a substantially cylindrical shape. One end portion of the second member 8 in the axial direction is an insertion portion 19 into which the base portion 9 of the first member 6 is inserted, and the other end portion is in the insertion portion 20 into which the discharge portion 42 of the syringe 2 is inserted. It has become. The cylindrical hole 19 a of the insertion portion 19 is set to a size corresponding to the base portion 9 of the first member 6.
 挿入部19には、第1部材6の接続片16に接続される固定片21が設けられている。この固定片21は、嵌入部20の先端に連続して半径外方向に突出するリング状のフランジとして形成されている。固定片21には、第1部材6に設けた接続片16の平面16bが当接し、固着される。固定片21と接続片16の固着方法としては、例えば、接着剤、超音波溶着、レーザ溶着、固定ねじ等を挙げることができる。 The insertion part 19 is provided with a fixing piece 21 connected to the connection piece 16 of the first member 6. The fixed piece 21 is formed as a ring-shaped flange that protrudes radially outward continuously from the tip of the fitting portion 20. A flat surface 16 b of the connection piece 16 provided on the first member 6 is brought into contact with and fixed to the fixed piece 21. Examples of the fixing method of the fixing piece 21 and the connection piece 16 include an adhesive, ultrasonic welding, laser welding, and a fixing screw.
 嵌入部20の筒孔20aは、シリンジ2の排出部42に対応した大きさに設定されており、挿入部19側に至るにつれて連続的に径が小さくなっている。嵌入部20の内面には、シリンジ2の排出部42を螺合させるためのねじ溝22が形成されている。 The cylinder hole 20a of the insertion part 20 is set to a size corresponding to the discharge part 42 of the syringe 2, and the diameter continuously decreases toward the insertion part 19 side. A thread groove 22 for screwing the discharge part 42 of the syringe 2 is formed on the inner surface of the fitting part 20.
 また、嵌入部20の内面において、ねじ溝22よりも挿入部19側には、筒孔20aの軸に向かって突出するストッパー23が設けられている。嵌入部20にシリンジ2を嵌入していくと、シリンジ2の排出部42がストッパー23に係止されることにより、それ以上のシリンジ2の嵌入が阻止される。
 これにより、排出部42の端面42aと針管3の基端3Bの間には、筒孔20aの軸方向に間隙が設けられている。
Further, on the inner surface of the fitting portion 20, a stopper 23 that protrudes toward the axis of the cylindrical hole 20 a is provided closer to the insertion portion 19 than the screw groove 22. When the syringe 2 is inserted into the insertion portion 20, the discharge portion 42 of the syringe 2 is locked by the stopper 23, thereby preventing further insertion of the syringe 2.
Thus, a gap is provided between the end face 42a of the discharge portion 42 and the base end 3B of the needle tube 3 in the axial direction of the tube hole 20a.
 また、図1に示すように、嵌入部20の外周面には、排出部42の嵌入が完了したことを認識させる認識部として、ハブ側表示部25が設けられている。排出部42を嵌入部20に嵌入した場合に、ハブ側表示部25は、排出部42に設けられた後述するシリンジ側表示部44と第2部材8の周方向で一致する。これにより、排出部42の嵌入部20への嵌入が完了したことを認識させることができる。したがって、本実施の形態では、針ハブ4のうち少なくとも第2部材8を透明或いは半透明の合成樹脂から形成し、嵌入部20を介してシリンジ側表示部44を視認できるようにしている。 As shown in FIG. 1, a hub side display unit 25 is provided on the outer peripheral surface of the insertion unit 20 as a recognition unit for recognizing that the insertion of the discharge unit 42 is completed. When the discharge part 42 is inserted into the insertion part 20, the hub side display part 25 coincides with a syringe side display part 44 (described later) provided in the discharge part 42 in the circumferential direction of the second member 8. Thereby, it can be made to recognize that the insertion to the insertion part 20 of the discharge part 42 was completed. Therefore, in the present embodiment, at least the second member 8 of the needle hub 4 is formed of a transparent or translucent synthetic resin so that the syringe-side display portion 44 can be visually recognized through the fitting portion 20.
 なお、本発明に係る認識部としては、シリンジ2のねじ部43又は嵌入部20のねじ溝22の一方の基端に凸部を設け、その凸部に係合する凹部を他方の基端に設けることにより形成してもよい。この場合は、凸部と凹部とが係合することにより、嵌入部20に対する排出部42の嵌入が完了したことを認識させることができる。 In addition, as a recognition part which concerns on this invention, a convex part is provided in one base end of the thread part 43 of the syringe 2 or the thread groove 22 of the insertion part 20, and the recessed part engaged with the convex part is made into the other base end. You may form by providing. In this case, it is possible to recognize that the insertion of the discharge portion 42 into the insertion portion 20 is completed by the engagement between the convex portion and the concave portion.
 挿入部19と嵌入部20との間には、弾性部材7が係合する係合部24が設けられている。この係合部24は、第2部材8の内面から半径内方向に突出する段部として形成されており、第2部材8の軸方向に略直交する係合面24a,24bを有している。係合部24の係合面24aには、弾性部材7の後述する第1のフランジ部72が係合され、係合面24bには、弾性部材7の第2のフランジ部73が係合される。 Between the insertion part 19 and the insertion part 20, the engaging part 24 with which the elastic member 7 engages is provided. The engaging portion 24 is formed as a step portion protruding radially inward from the inner surface of the second member 8, and has engaging surfaces 24 a and 24 b that are substantially orthogonal to the axial direction of the second member 8. . A first flange portion 72 (to be described later) of the elastic member 7 is engaged with the engagement surface 24a of the engagement portion 24, and a second flange portion 73 of the elastic member 7 is engaged with the engagement surface 24b. The
 次に、弾性部材7について説明する。
 弾性部材7は、針ハブ4の第2部材8内に配置され、針管3を保持する第1部材6とシリンジ2との間に介在される。この弾性部材7は、本体部70と、この本体部70の軸方向の一端に設けられた第1のフランジ部72と、本体部70の他端に設けられた第2のフランジ部73を有している。
Next, the elastic member 7 will be described.
The elastic member 7 is disposed in the second member 8 of the needle hub 4 and is interposed between the first member 6 that holds the needle tube 3 and the syringe 2. The elastic member 7 includes a main body portion 70, a first flange portion 72 provided at one end of the main body portion 70 in the axial direction, and a second flange portion 73 provided at the other end of the main body portion 70. is doing.
 本体部70は、略円柱状に形成されており、軸方向に垂直な端面70a,70bを有している。本体部70の端面70aには、第1部材6におけるベース部9の端面9bが当接している。また、本体部70の端面70bは、シリンジ2の排出部42の端面42aと離間しており、その間には空隙が存在している。 The main body 70 is formed in a substantially cylindrical shape and has end faces 70a and 70b perpendicular to the axial direction. The end surface 9 b of the base portion 9 of the first member 6 is in contact with the end surface 70 a of the main body portion 70. Moreover, the end surface 70b of the main-body part 70 is spaced apart from the end surface 42a of the discharge | emission part 42 of the syringe 2, and the space | gap exists between them.
 本体部70には、第1部材6のベース部9の端面9bから突出した針管3の基端3B側が挿通される挿通孔71が設けられている。この挿通孔71は、本体部70の軸方向に延びており、端面70a,70bに開口されている。本体部70の内面は、ベース側離間部74と、シリンジ側離間部75と、密着部76から形成されている。 The main body portion 70 is provided with an insertion hole 71 through which the proximal end 3B side of the needle tube 3 protruding from the end surface 9b of the base portion 9 of the first member 6 is inserted. The insertion hole 71 extends in the axial direction of the main body 70 and is opened to the end faces 70a and 70b. The inner surface of the main body portion 70 is formed by a base side separation portion 74, a syringe side separation portion 75, and a close contact portion 76.
 ベース側離間部74は、端面70aにおける挿通孔71の開口を形成する。このベース側離間部74は、針管3の外周面から離間しており、端面70aに向かうにつれて挿通孔71の径が連続的に大きくなるようなテーパー状に形成されている。これにより、ベース部9の端面9bから突出した針管3の基端3B側を挿通孔71に容易に挿通することができる。なお、挿通孔71におけるベース側離間部74の形状は、針管3が挿通孔71に挿通し易い形状であれば、テーパー状に限定されるものではない。 The base side separation portion 74 forms an opening of the insertion hole 71 in the end surface 70a. The base-side separation portion 74 is separated from the outer peripheral surface of the needle tube 3 and is formed in a tapered shape such that the diameter of the insertion hole 71 continuously increases toward the end surface 70a. Thereby, the base end 3 </ b> B side of the needle tube 3 protruding from the end surface 9 b of the base portion 9 can be easily inserted into the insertion hole 71. Note that the shape of the base-side separation portion 74 in the insertion hole 71 is not limited to a tapered shape as long as the needle tube 3 can be easily inserted into the insertion hole 71.
 シリンジ側離間部75は、端面70bにおける挿通孔71の開口を形成する。このシリンジ側離間部75は、針管3の外周面から離間しており、端面70bに向かうにつれて挿通孔71の径が連続的に大きくなるようなテーパー状に形成されている。弾性部材7にシリンジ側離間部75を設けることにより、本体部70の端面70b側が、薬剤注入時の圧力により弾性変形して針管3の基端3Bを覆うことを防止することができる。 The syringe side separation part 75 forms the opening of the insertion hole 71 in the end surface 70b. The syringe-side separation portion 75 is separated from the outer peripheral surface of the needle tube 3, and is formed in a taper shape such that the diameter of the insertion hole 71 continuously increases toward the end surface 70b. By providing the syringe-side separation portion 75 on the elastic member 7, it is possible to prevent the end surface 70b side of the main body portion 70 from being elastically deformed by the pressure at the time of drug injection and covering the proximal end 3B of the needle tube 3.
 シリンジ側離間部75には、針側弁体部77が設けられている。この針側弁体部77は、針管3の外周を覆う筒状の突部として形成されている。この針側弁体部77の外周面は、先端に向かうにつれて径が連続的に小さくなるようなテーパー状に形成されている。
 薬剤注射装置100の使用時においてシリンジ側離間部75に薬剤が流れると、その薬剤によって針側弁体部77が押圧され、針管3に密着するように変形する。これにより耐圧性能を向上させることが可能であり、針管3と弾性部材7との間に薬剤が浸入するのを抑制できる。
A needle-side valve element 77 is provided in the syringe-side separation part 75. The needle side valve body 77 is formed as a cylindrical protrusion that covers the outer periphery of the needle tube 3. The outer peripheral surface of the needle side valve body 77 is formed in a taper shape whose diameter continuously decreases toward the tip.
When a drug flows into the syringe-side separation portion 75 during use of the drug injection device 100, the needle-side valve body 77 is pressed by the drug and deforms so as to be in close contact with the needle tube 3. Thereby, the pressure resistance performance can be improved, and the invasion of the medicine between the needle tube 3 and the elastic member 7 can be suppressed.
 密着部76は、ベース側離間部74とシリンジ側離間部75との間に形成されている。この密着部76は、針管3の外周面に液密に密着し、シリンジ2内の薬剤が針管3と弾性部材7との間に浸入して、針ハブ4の第1部材6側へ漏れることを防止する。 The contact portion 76 is formed between the base side separation portion 74 and the syringe side separation portion 75. The contact portion 76 is in liquid-tight contact with the outer peripheral surface of the needle tube 3, and the medicine in the syringe 2 enters between the needle tube 3 and the elastic member 7 and leaks to the first member 6 side of the needle hub 4. To prevent.
 第1のフランジ部72は、本体部70の外周面から半径外方向に突出するリング状に形成されている。この第1のフランジ部72の外径は、第1部材6のベース部9の外径と略等しくなっている。弾性部材7は、第2部材8の係合部24と第1部材6のベース部9によって第1のフランジ部72が挟持されることにより、針ハブ4に取り付けられている。 The first flange portion 72 is formed in a ring shape that protrudes radially outward from the outer peripheral surface of the main body portion 70. The outer diameter of the first flange portion 72 is substantially equal to the outer diameter of the base portion 9 of the first member 6. The elastic member 7 is attached to the needle hub 4 by holding the first flange portion 72 between the engaging portion 24 of the second member 8 and the base portion 9 of the first member 6.
 第2のフランジ部73は、第1のフランジ部72と同様に、本体部70の外周面から半径外方向に突出するリング状に形成されている。この第2のフランジ部73は、第2部材8に設けた係合部24の係合面24bに係合する。弾性部材7は、第1のフランジ部72及び第2のフランジ部73が第2部材8の係合部24に係合することにより、軸方向への移動が係止されている。これにより、薬剤が弾性部材7と第2部材8との間に浸入して第1部材6側へ漏れることを防止することができ、耐圧性能を向上させることができる。 The second flange portion 73 is formed in a ring shape that protrudes radially outward from the outer peripheral surface of the main body portion 70, similarly to the first flange portion 72. The second flange portion 73 engages with the engagement surface 24 b of the engagement portion 24 provided on the second member 8. The elastic member 7 is locked to move in the axial direction by the first flange portion 72 and the second flange portion 73 engaging the engaging portion 24 of the second member 8. Thereby, it can prevent that a chemical | medical agent permeates between the elastic member 7 and the 2nd member 8, and leaks to the 1st member 6 side, and can improve a pressure | voltage resistant performance.
 弾性部材7の材質としては、合成ゴム、天然ゴム、シリコーンゴム、イソブチレンゴムのような各種ゴム材料や、ポリウレタン系、スチレン系等の各種熱可塑性エラストマー、或いはそれらの混合物等の弾性材料が挙げられる。 Examples of the material of the elastic member 7 include various rubber materials such as synthetic rubber, natural rubber, silicone rubber, and isobutylene rubber, various thermoplastic elastomers such as polyurethane and styrene, or mixtures thereof. .
[シリンジ]
 シリンジ2は、シリンジ本体41と、このシリンジ本体41に連続する排出部42を備えている。シリンジ本体41は、円形の筒体からなっている。排出部42は、シリンジ本体41の軸方向の一端から突出しており、シリンジ本体41よりも小さい外径の円形の筒体からなっている。この排出部42は、先端に向かうにつれて径が連続的に小さくなるようなテーパー状に形成されている。
[Syringe]
The syringe 2 includes a syringe body 41 and a discharge portion 42 that is continuous with the syringe body 41. The syringe body 41 is formed of a circular cylinder. The discharge part 42 protrudes from one end of the syringe body 41 in the axial direction, and is composed of a circular cylinder having an outer diameter smaller than that of the syringe body 41. The discharge portion 42 is formed in a tapered shape whose diameter continuously decreases toward the tip.
 排出部42の先端となる端面42aは、例えば第2部材8の内壁面に設けられたストッパー23に当接することにより、針ハブ4に対するシリンジ2の嵌入深さが制限される。これにより、針管3の軸方向において、端面42aと針管3の基端3Bの間に間隙が設けられている。
 また、図2に示すように、シリンジ本体41の端面41aが第2部材8の嵌入部20の先端に当接することによりシリンジ2の嵌入深さを制限してもよく、端面42aと針管3の基端3Bの間に所定の間隙を設けるものであれば、その他の構成を用いてよい。
For example, the end surface 42 a that is the tip of the discharge portion 42 abuts against a stopper 23 provided on the inner wall surface of the second member 8, thereby limiting the insertion depth of the syringe 2 with respect to the needle hub 4. Thereby, a gap is provided between the end face 42 a and the proximal end 3 </ b> B of the needle tube 3 in the axial direction of the needle tube 3.
In addition, as shown in FIG. 2, the insertion depth of the syringe 2 may be limited by the end surface 41 a of the syringe main body 41 coming into contact with the distal end of the insertion portion 20 of the second member 8, and the end surface 42 a and the needle tube 3 may be limited. Other configurations may be used as long as a predetermined gap is provided between the base ends 3B.
 図1に示すように、排出部42の外周面には、針ハブ4の第2部材8に螺合させるためのねじ部43と、シリンジ側表示部44が設けられている。このシリンジ側表示部44は、針ハブ4に設けた嵌入部20に排出部42を嵌入する場合に、針ハブ4の第2部材8を介して認識される。そして、排出部42が嵌入部20の係合部24に当接し、嵌入が完了すると、シリンジ側表示部44は、針ハブ4のハブ側表示部25と周方向で一致する。 As shown in FIG. 1, the outer peripheral surface of the discharge portion 42 is provided with a screw portion 43 for screwing onto the second member 8 of the needle hub 4 and a syringe-side display portion 44. The syringe-side display unit 44 is recognized via the second member 8 of the needle hub 4 when the discharge unit 42 is inserted into the insertion unit 20 provided in the needle hub 4. And when the discharge part 42 contacts the engaging part 24 of the insertion part 20 and the insertion is completed, the syringe side display part 44 coincides with the hub side display part 25 of the needle hub 4 in the circumferential direction.
 シリンジ本体41内には、ガスケット(不図示)が収納されている。シリンジ本体41内の空間は、ガスケットにより液密に仕切られており、排出部42に連通する一方の空間は、排出部42内の空間と共に液室46を形成している。シリンジ本体41内の他方の空間には、プランジャ(不図示)が配置される。プランジャは、ガスケットに接続されており、シリンジ本体41の他端の開口から突出している。このプランジャを操作することにより、ガスケットがシリンジ本体41内で軸方向に移動され、シリンジ本体41に充填された薬剤の排出が行われる。 In the syringe body 41, a gasket (not shown) is accommodated. The space in the syringe body 41 is liquid-tightly partitioned by a gasket, and one space communicating with the discharge part 42 forms a liquid chamber 46 together with the space in the discharge part 42. In the other space in the syringe body 41, a plunger (not shown) is arranged. The plunger is connected to the gasket and protrudes from the opening at the other end of the syringe body 41. By operating this plunger, the gasket is moved in the axial direction in the syringe body 41, and the medicine filled in the syringe body 41 is discharged.
 また、このシリンジ2は、薬剤(薬液)80が充填された後にエア抜きが行われており、内部の空気が予め排出されている。特にこの場合には、シリンジ2内部に空気が残るのを抑制するために、シリンジ2の容量よりも僅かに多い量の薬剤80をシリンジ2に注入し、排出口42bにおいて液滴81をあえて形成しておくことが望ましい。
 シリンジ本体41及び排出部42の材質としては、ポリカーボネート、ポリプロピレン、ポリエチレン等の合成樹脂を用いることができ、また、ガラス等を用いてもよい。
In addition, the syringe 2 is vented after the medicine (chemical solution) 80 is filled, and the internal air is discharged in advance. Particularly in this case, in order to prevent air from remaining in the syringe 2, an amount of medicine 80 slightly larger than the volume of the syringe 2 is injected into the syringe 2, and a droplet 81 is formed at the discharge port 42 b. It is desirable to keep it.
As a material of the syringe main body 41 and the discharge part 42, synthetic resins such as polycarbonate, polypropylene, and polyethylene can be used, and glass or the like may be used.
 また、本実施の形態では、針管3の基端3Bとシリンジ2の排出部42の端面42aとの間に空隙を設けている。シリンジ2の排出部42には排出口42bが開口され、シリンジ2の内部空間が嵌入部20の内部空間に連通した状態で嵌入部20に嵌入されている。 In the present embodiment, a gap is provided between the proximal end 3B of the needle tube 3 and the end surface 42a of the discharge portion 42 of the syringe 2. A discharge port 42 b is opened in the discharge part 42 of the syringe 2, and the syringe 2 is inserted into the insertion part 20 in a state where the internal space communicates with the internal space of the insertion part 20.
[キャップ]
 図3は、シリンジ2と針ハブ4とキャップ5が組み付けられた状態で提供される本実施形態の薬剤注射装置100の断面図である。
 キャップ5は、筒孔51aが設けられた第1筒部51と、第1筒部51に連続し、筒孔51aに連通する筒孔52aが設けられた第2筒部52と、第2筒部52に連続し、筒孔52aに連通する凹部53aが設けられた底部53とを有している。
[cap]
FIG. 3 is a cross-sectional view of the drug injection device 100 of the present embodiment provided with the syringe 2, the needle hub 4, and the cap 5 assembled.
The cap 5 includes a first tube portion 51 provided with a tube hole 51a, a second tube portion 52 provided with a tube hole 52a that is continuous with the first tube portion 51 and communicates with the tube hole 51a, and a second tube. And a bottom portion 53 provided with a recess 53a that is continuous with the portion 52 and communicates with the cylindrical hole 52a.
 第1筒部51は、例えば円筒形状をしており、針ハブ4を挿入するための開口をキャップ5に形成している。第1筒部51の筒孔51aの径は、ガイド部12の径よりも大きく構成されており、針ハブ4が筒孔51aから挿入される。 The first tube portion 51 has, for example, a cylindrical shape, and an opening for inserting the needle hub 4 is formed in the cap 5. The diameter of the cylinder hole 51a of the first cylinder part 51 is configured to be larger than the diameter of the guide part 12, and the needle hub 4 is inserted from the cylinder hole 51a.
 第2筒部52は、第1筒部51に連続して形成されており、筒孔52aの軸は、筒孔51aの軸と一致している。
 また、この筒孔52aの径は、ガイド部12の径にほぼ等しく、筒孔51aの径よりも小さい。本実施の形態では、第2筒部52の内面52bより突出する突出部52cによって筒孔52aの径が規定されている。
The 2nd cylinder part 52 is formed following the 1st cylinder part 51, and the axis | shaft of the cylinder hole 52a corresponds with the axis | shaft of the cylinder hole 51a.
The diameter of the cylindrical hole 52a is substantially equal to the diameter of the guide portion 12, and is smaller than the diameter of the cylindrical hole 51a. In the present embodiment, the diameter of the cylindrical hole 52a is defined by the protruding portion 52c protruding from the inner surface 52b of the second cylindrical portion 52.
 この第2筒部52に針ハブ4のガイド部12が嵌合し、針ハブ4がキャップ5に固定される。
 筒孔52aを形成する突出部52cの壁面は、底部53側に向かって筒孔52aの径が小さくなるテーパー形状に形成されていてもよい。
The guide portion 12 of the needle hub 4 is fitted to the second cylindrical portion 52, and the needle hub 4 is fixed to the cap 5.
The wall surface of the protrusion 52c that forms the cylindrical hole 52a may be formed in a tapered shape in which the diameter of the cylindrical hole 52a decreases toward the bottom 53 side.
 底部53は、第2筒部52に連続して形成されている。底部53の凹部53aは円形に形成されており、この凹部53aの軸は、筒孔52aの軸と一致している。
 また、この凹部53aの径は、安定部11の径にほぼ等しく、筒孔52aの径よりも小さい。
The bottom portion 53 is formed continuously with the second cylinder portion 52. The recess 53a of the bottom 53 is formed in a circular shape, and the axis of the recess 53a coincides with the axis of the cylinder hole 52a.
Further, the diameter of the concave portion 53a is substantially equal to the diameter of the stable portion 11 and is smaller than the diameter of the cylindrical hole 52a.
 底部53は、第2筒部52の内面52bもしくは突出部52cの壁面(筒孔52a)から連続する内面53bより突出する突出部53cが形成されている。凹部53aの径は、この突出部53cによって規定されている。
 凹部53aに第1部材6の安定部11が嵌合され、針ハブ4がキャップ5に固定される。
 凹部53aは、後述する膨出部54に向かうにつれて径が小さくなるテーパー形状に形成されていてもよい。
The bottom 53 is formed with a protruding portion 53c that protrudes from an inner surface 53b continuous from the inner surface 52b of the second cylindrical portion 52 or the wall surface (cylinder hole 52a) of the protruding portion 52c. The diameter of the recess 53a is defined by the protrusion 53c.
The stable portion 11 of the first member 6 is fitted into the recess 53 a, and the needle hub 4 is fixed to the cap 5.
The concave portion 53a may be formed in a tapered shape having a diameter that decreases toward the bulging portion 54 described later.
 凹部53aの中央部には、キャップ5の内側に膨出する膨出部54が形成されている。
 この膨出部54には、針管3の先端3Aから漏れ出た薬剤80を回収する回収部55が設けられている。この回収部55は、膨出部54から突出する突起によって構成されており、筒孔55aを有する筒状に形成されている。この回収部55によって、針管3の先端3Aから漏れ出た薬剤80が回収される。
A bulging portion 54 that bulges inside the cap 5 is formed at the center of the recess 53a.
The bulging portion 54 is provided with a collecting portion 55 for collecting the medicine 80 leaking from the tip 3A of the needle tube 3. The collection part 55 is constituted by a protrusion protruding from the bulging part 54 and is formed in a cylindrical shape having a cylindrical hole 55a. The medicine 80 leaked from the tip 3A of the needle tube 3 is collected by the collection unit 55.
 この回収部55について以下に説明する。
 本実施形態の薬剤注射装置100を用いる場合には、まず予め薬剤80を充填したシリンジ2に対してエア抜きを行った後、このシリンジ2を、キャップ5内に収納され、針先3Aを下方に向けた状態の針ハブ4に取り付ける。このため、シリンジ2の排出口42bには薬剤80による液滴81が形成されている。また、仮にエア抜きを行っていないとしても、薬剤80の自重により液滴81が形成される可能性がある。
The collection unit 55 will be described below.
When using the medicine injection device 100 of the present embodiment, first, the syringe 2 pre-filled with the medicine 80 is vented, and then the syringe 2 is housed in the cap 5 and the needle tip 3A is moved downward. The needle hub 4 is attached to the needle hub 4 in the state of facing. For this reason, the droplet 81 by the chemical | medical agent 80 is formed in the discharge port 42b of the syringe 2. FIG. Even if the air is not vented, the droplet 81 may be formed due to the weight of the medicine 80.
 例えば、本実施の形態による薬剤注射装置100に対し、シリンジ2の排出部42を弾性部材7に当接させるように構成された薬剤注射装置110を比較例として図4に示す。
 なお、本実施の形態による薬剤注射装置100(図2)と対応する部位には、図2と同符号を付し重複を避けるものとする。
For example, FIG. 4 shows a drug injection device 110 configured to bring the discharge portion 42 of the syringe 2 into contact with the elastic member 7 with respect to the drug injection device 100 according to the present embodiment as a comparative example.
It should be noted that parts corresponding to those of the drug injection device 100 (FIG. 2) according to the present embodiment are denoted by the same reference numerals as those in FIG.
 図4に示す薬剤注射装置110は、第2部材8の嵌入部20において、筒孔20aの壁面にはストッパーが設けられていない。嵌入部20に嵌入されたシリンジ2の排出部42は弾性部材7に当接し、排出部42の端面42aにおいて、弾性部材7の端面70bに液密に接している。それ以外は、図2に示した薬剤注射装置100と同じである。 In the drug injection device 110 shown in FIG. 4, no stopper is provided on the wall surface of the cylindrical hole 20 a in the insertion portion 20 of the second member 8. The discharge part 42 of the syringe 2 inserted into the insertion part 20 is in contact with the elastic member 7, and is in liquid-tight contact with the end surface 70 b of the elastic member 7 at the end surface 42 a of the discharge part 42. The rest is the same as the drug injection device 100 shown in FIG.
 この場合、図4に示すように、シリンジ2の排出部42に形成された液滴81は、針管3の基端3Bに接触してしまっている。
 液滴81が針管3の基端3Bに接触すると、シリンジ2内の薬剤80が毛細管現象によって針管3の内部に浸入していく。これにより、針管3の針先3Aから薬剤80が僅かに漏れ出し、液滴82が形成されてしまうことがある。
In this case, as shown in FIG. 4, the droplet 81 formed on the discharge part 42 of the syringe 2 has been in contact with the proximal end 3 </ b> B of the needle tube 3.
When the droplet 81 comes into contact with the proximal end 3B of the needle tube 3, the medicine 80 in the syringe 2 enters the inside of the needle tube 3 by capillary action. As a result, the medicine 80 may slightly leak from the needle tip 3A of the needle tube 3 and a droplet 82 may be formed.
 また、一般的にシリンジを針ハブに取り付ける際には、シリンジと針ハブの嵌合箇所において液漏れが生じないように、液密に嵌合させる必要がある。このため、図1や図4に示した薬剤注射装置100,110では、排出部42の外壁面を筒孔20aの内壁面に面接触させる等により、排出部42を嵌入部20に液密に嵌入させている。したがって、排出部42の嵌入時において、排出部42の端面42aと弾性部材7の端面70aとの間の筒孔20aの内部空間は、ある程度気密性を有している。
 このため、シリンジ2の排出部42を嵌入部20に嵌入させていくと、筒孔20a内の気体が圧縮され嵌入部20内の気圧が上昇する。したがって、液滴81が針管3の基端3Bに接触すると、この気圧によっても薬剤80が針管3の内部に押し出され、針先3Aから薬剤80が漏出する。
In general, when the syringe is attached to the needle hub, it is necessary to fit the syringe in a liquid-tight manner so that liquid leakage does not occur at the fitting portion between the syringe and the needle hub. For this reason, in the medicine injection devices 100 and 110 shown in FIG. 1 and FIG. 4, the discharge portion 42 is made fluid-tight to the fitting portion 20 by bringing the outer wall surface of the discharge portion 42 into surface contact with the inner wall surface of the cylindrical hole 20 a. It is inserted. Therefore, when the discharge portion 42 is fitted, the internal space of the cylindrical hole 20a between the end surface 42a of the discharge portion 42 and the end surface 70a of the elastic member 7 is airtight to some extent.
For this reason, if the discharge part 42 of the syringe 2 is inserted in the insertion part 20, the gas in the cylinder hole 20a will be compressed and the atmospheric pressure in the insertion part 20 will rise. Therefore, when the droplet 81 comes into contact with the proximal end 3B of the needle tube 3, the drug 80 is pushed out into the needle tube 3 by this atmospheric pressure, and the drug 80 leaks from the needle tip 3A.
 このような液漏れが生じていると、投与時において薬剤注射装置110を取り出したときに液滴が落下し、周囲に薬品を付着させる可能性がある。また、液滴が針先に付いたまま注射を行うと、液滴が患者の肌に付着することも考えられる。 If such a liquid leak occurs, there is a possibility that when the drug injection device 110 is taken out at the time of administration, the liquid droplet falls and attaches chemicals to the surroundings. It is also conceivable that when an injection is carried out with the droplet attached to the needle tip, the droplet adheres to the patient's skin.
 これに対し、本実施形態による薬剤注射装置100では、図3に示すように、針管3から漏れ出た薬剤80を回収する回収部55をキャップ5の内壁面に設けている。このため、液滴81が針管3の基端3Bに接触したとしても、針ハブ4からキャップ5を取り外した際には、針管3の先端3Aに薬剤80の液滴が形成されない。したがって、薬剤80の液滴が周囲に付着したり、液滴が針管3に付着したまま、患者に注射するのを防止することができる。 On the other hand, in the medicine injection device 100 according to the present embodiment, as shown in FIG. 3, a collecting portion 55 for collecting the medicine 80 leaking from the needle tube 3 is provided on the inner wall surface of the cap 5. For this reason, even if the droplet 81 comes into contact with the proximal end 3B of the needle tube 3, when the cap 5 is removed from the needle hub 4, a droplet of the medicine 80 is not formed on the distal end 3A of the needle tube 3. Accordingly, it is possible to prevent the medicine 80 from adhering to the surroundings or injecting the patient into the patient while the liquid droplet is attached to the needle tube 3.
 このように、本実施形態では、内部に薬剤80が充填され、予めエア抜きが行われたシリンジ2を用いることにより針先3Aから薬剤80が漏れ出たとしても、針先3Aには液滴が形成されない。このため、内部に薬剤80が充填され、エア抜きが行われたシリンジ2を注射針組立体1に予め取り付けておくことが可能となり、針ハブに取り付けた後にシリンジ内の空気を排出する作業が必要ない。また、針先3Aには液滴が形成されないので、周囲に薬品を付着させるのを抑制できる。
 なお、針先3Aから薬剤80が漏れ出ても、針先3Aには液滴が形成されないので、シリンジ2の排出部42の端面42aを弾性部材7の端面70bに当接させるように薬剤注射装置100を構成することも可能である。
As described above, in this embodiment, even when the medicine 80 leaks from the needle tip 3A by using the syringe 2 filled with the medicine 80 and previously vented, a droplet is dropped on the needle tip 3A. Is not formed. For this reason, the syringe 2 filled with the medicine 80 and evacuated can be attached in advance to the injection needle assembly 1, and the work of discharging the air in the syringe after being attached to the needle hub is possible. unnecessary. In addition, since no droplet is formed on the needle tip 3A, it is possible to prevent chemicals from adhering to the surroundings.
Even if the medicine 80 leaks from the needle tip 3A, no liquid droplet is formed on the needle tip 3A. Therefore, the medicine injection is performed so that the end surface 42a of the discharge portion 42 of the syringe 2 contacts the end surface 70b of the elastic member 7. It is also possible to configure the device 100.
 本実施形態において、回収部55は、キャップ5の内壁面から突出する突起によって構成されている。また、この突起は、針管3の針先3Aの近傍に配置される。
 針管3の針先3Aに液滴が形成されると、その液滴は、針管3の針先3Aの近傍に配置された回収部55に接触する。回収部55に接触した液滴は、その自重等により回収部55の壁面を伝って、あるいは、回収部55の筒孔55aの底に転写して移動し、筒孔55a内に溜められる。
 このとき、薬剤80としては、例えばワクチンのような表面張力が小さい液体であるほど、針先3Aから回収部55へ液滴を容易に移動させることができる。
In the present embodiment, the collection unit 55 is configured by a protrusion protruding from the inner wall surface of the cap 5. Further, this protrusion is arranged in the vicinity of the needle tip 3 </ b> A of the needle tube 3.
When a droplet is formed on the needle tip 3 </ b> A of the needle tube 3, the droplet comes into contact with the recovery unit 55 disposed in the vicinity of the needle tip 3 </ b> A of the needle tube 3. The liquid droplet that has contacted the collection unit 55 travels along the wall surface of the collection unit 55 due to its own weight or the like, or is transferred to the bottom of the cylindrical hole 55a of the collection unit 55 and moved to be accumulated in the cylindrical hole 55a.
At this time, as the medicine 80, for example, a liquid having a smaller surface tension such as a vaccine, the liquid droplet can be easily moved from the needle tip 3A to the collection unit 55.
 また、針先3Aの軸に垂直な面内方向において、回収部55と針先3Aの距離、すなわち針先3Aと筒孔55aの底との距離は0.5mm以上3mm以下であることが好ましい。
 これにより、針先3Aが回収部55に接触して損傷することなく、針先3Aに形成された液滴のみを回収部55の壁面あるいは筒孔55aの底に接触させることができる。
In the in-plane direction perpendicular to the axis of the needle tip 3A, the distance between the collection portion 55 and the needle tip 3A, that is, the distance between the needle tip 3A and the bottom of the tube hole 55a is preferably 0.5 mm or more and 3 mm or less. .
Thus, only the droplet formed on the needle tip 3A can be brought into contact with the wall surface of the collecting portion 55 or the bottom of the cylindrical hole 55a without the needle tip 3A coming into contact with the collecting portion 55 and being damaged.
 なお、この場合は、回収部55の壁面に液滴を付着させるので、針管3の針先3Aの少なくとも一部が、回収部55の筒孔55a内に位置している。すなわち、針管3の軸方向において、針管3と回収部55は交差していることが望ましい。 In this case, since the liquid droplets are attached to the wall surface of the collection unit 55, at least a part of the needle tip 3A of the needle tube 3 is located in the cylindrical hole 55a of the collection unit 55. That is, it is desirable that the needle tube 3 and the collection unit 55 intersect in the axial direction of the needle tube 3.
 また、針先3Aに形成された液滴が回収部55の壁面に付着し、回収部55側に移動しやすくするために、回収部55の表面は、薬剤80に対して、針管3よりも濡れ性が高いことが好ましい。
 キャップ5(底部53)の構成材料が、薬剤80に対して針管3よりも濡れ性が高い場合には、回収部55を底部53と一体に成型していてもよい。また、薬剤80に対して針管3よりも濡れ性が高い材料による別部材を取り付けることにより、回収部55を形成してもよい。
 また、例えばプラズマ放電や紫外線照射等の表面処理により、回収部55の濡れ性を向上させてもよい。
Further, in order to make the droplet formed on the needle tip 3A adhere to the wall surface of the collection unit 55 and easily move to the collection unit 55 side, the surface of the collection unit 55 is more than the needle tube 3 with respect to the medicine 80. High wettability is preferred.
When the constituent material of the cap 5 (bottom part 53) has higher wettability than the needle tube 3 with respect to the medicine 80, the recovery part 55 may be molded integrally with the bottom part 53. Further, the collection unit 55 may be formed by attaching another member made of a material having higher wettability than the needle tube 3 to the medicine 80.
Further, the wettability of the collection unit 55 may be improved by surface treatment such as plasma discharge or ultraviolet irradiation.
 本実施の形態では、キャップ5の底部53に筒状の突起を設けることで、針先3Aに形成される液滴を回収する構成としているが、液滴をキャップ5側に付着させるものであれば、その他の構成を用いてもよい。例えば、針管3の軸方向に近接する突起を設け、針管3の軸方向に液滴を移動させることにより、突起に液滴を付着させてもよい。また、凹部53aを形成する底部53の壁面から突出する突起を設け、針管3の軸に垂直な面内方向において、この突起から針管3までの距離を上述の距離に設定することにより、この突起に液滴を付着させるようにしてもよい。 In the present embodiment, the configuration is such that a liquid drop formed on the needle tip 3A is collected by providing a cylindrical projection on the bottom 53 of the cap 5, but the liquid drop may be attached to the cap 5 side. For example, other configurations may be used. For example, a protrusion close to the axial direction of the needle tube 3 may be provided, and the droplet may be attached to the protrusion by moving the droplet in the axial direction of the needle tube 3. Further, by providing a protrusion protruding from the wall surface of the bottom 53 forming the recess 53a, and setting the distance from the protrusion to the needle tube 3 in the in-plane direction perpendicular to the axis of the needle tube 3, the protrusion You may make it make a droplet adhere to.
 ただし、本実施の形態のように、回収部55を筒状に形成し、その筒孔55a内に針先3Aを配置する場合には、回収した液滴を筒孔55a内に留めおくことができる。
 また、筒孔55aの径が小さいと、筒孔55aを形成する回収部55の内面に接触させることなく針先3Aを筒孔55aに挿入するのが困難となる場合があるが、針先3Aから回収部55の内面までの最短距離が上述の距離内であればよい。すなわち、針先3Aは筒孔55aの中心軸上に位置する必要はなく、回収部55の少なくとも一点が針先3Aに対して上述の距離内にあればよい。
However, when the collecting portion 55 is formed in a cylindrical shape and the needle tip 3A is disposed in the cylindrical hole 55a as in the present embodiment, the collected liquid droplets can be retained in the cylindrical hole 55a. it can.
In addition, if the diameter of the cylinder hole 55a is small, it may be difficult to insert the needle tip 3A into the cylinder hole 55a without making contact with the inner surface of the collection part 55 that forms the cylinder hole 55a. The shortest distance from the inner surface of the collection unit 55 to the inner surface of the collection unit 55 may be within the above-described distance. That is, the needle tip 3A does not have to be located on the central axis of the cylindrical hole 55a, and at least one point of the collecting portion 55 only needs to be within the above-mentioned distance from the needle tip 3A.
2.第2の実施の形態(軟材を配置し、軟材内部に針管の針先を埋設する例)
 図5は、本実施の形態による薬剤注射装置200の構成を示す断面図である。第1の実施の形態による薬剤注射装置100(図3参照)と同一の構成をとることが可能な部位については、図3と同一符号を付している。
2. Second Embodiment (Example in which soft material is arranged and the needle tip of a needle tube is embedded in the soft material)
FIG. 5 is a cross-sectional view showing a configuration of the medicine injection device 200 according to the present embodiment. Parts that can have the same configuration as that of the medicine injection device 100 (see FIG. 3) according to the first embodiment are denoted by the same reference numerals as those in FIG.
 本実施の形態による薬剤注射装置200は、皮膚に穿刺される針先3Aと、針先3Aと反対側の基端3Bを有する針管3と、針管3を保持する針ハブ4と、針ハブ4に接続され、内部に薬剤80が充填されたシリンジ2を備える。また、例えばこの針ハブ4に嵌合し、針管3の針先3Aを覆うキャップ5aを備える。
 また、注射針組立体1Aは、この針管3と針ハブ4とキャップ5によって構成されている。
The drug injection device 200 according to the present embodiment includes a needle tip 3A that is punctured into the skin, a needle tube 3 having a proximal end 3B opposite to the needle tip 3A, a needle hub 4 that holds the needle tube 3, and a needle hub 4 And a syringe 2 filled with a medicine 80 inside. Further, for example, a cap 5 a that is fitted to the needle hub 4 and covers the needle tip 3 A of the needle tube 3 is provided.
The injection needle assembly 1 </ b> A includes the needle tube 3, the needle hub 4, and the cap 5.
 本実施の形態において、シリンジ2と、針管3と、針ハブ4は、第1の実施の形態と同一のものが用いられる。したがって、シリンジ2は、内部に薬剤80が充填された後、予めエア抜きが行われている。このため、その排出口42bには、薬剤80による液滴81が形成されている。 In the present embodiment, the same syringe 2, needle tube 3, and needle hub 4 as those in the first embodiment are used. Therefore, the syringe 2 is pre-bleeded after the medicine 80 is filled therein. For this reason, the droplet 81 by the chemical | medical agent 80 is formed in the discharge port 42b.
 キャップ5aは、筒孔51aが設けられた第1筒部51と、第1筒部51に連続し、筒孔51aに連通する筒孔52aが設けられた第2筒部52と、第2筒部52に連続し、筒孔52aに連通する凹部53aが設けられた底部53とを有している。
 これらの構成も第1の実施の形態と同様であり、底部53の膨出部54には、針管3の針先3Aに形成された液滴を回収する回収部55Aが設けられている。
The cap 5a includes a first tube portion 51 provided with a tube hole 51a, a second tube portion 52 provided with a tube hole 52a that is continuous with the first tube portion 51 and communicates with the tube hole 51a, and a second tube. And a bottom portion 53 provided with a recess 53a that is continuous with the portion 52 and communicates with the cylindrical hole 52a.
These configurations are also the same as in the first embodiment, and the bulging portion 54 of the bottom portion 53 is provided with a collecting portion 55A for collecting the droplets formed on the needle tip 3A of the needle tube 3.
 この回収部55Aは、例えば筒孔56aを有する筒状の突起56と、筒孔56aの内部に配設され、針管3の針先3Aを穿刺可能な軟材57とを有する。
 この軟材57は例えば、発泡ポリウレタン、ポリアクリルアミドゲル等の薬剤80を吸収する吸収体を用いることができる。薬剤80を吸収する吸収体に針先3Aを穿刺しておくことで、針先3Aから漏れ出た薬剤80により液滴が形成されるのを確実に防止することができる。
 また、薬剤80を軟材57に吸収させることにより、漏れ出た薬剤80を一箇所に留めておくことができる。
The recovery unit 55A includes, for example, a cylindrical protrusion 56 having a cylindrical hole 56a, and a soft material 57 that is disposed inside the cylindrical hole 56a and can puncture the needle tip 3A of the needle tube 3.
As this soft material 57, for example, an absorbent body that absorbs the medicine 80 such as foamed polyurethane and polyacrylamide gel can be used. By puncturing the needle tip 3A into the absorbent body that absorbs the medicine 80, it is possible to reliably prevent a droplet from being formed by the medicine 80 leaking from the needle tip 3A.
Further, by allowing the soft medicine 57 to absorb the medicine 80, it is possible to keep the leaked medicine 80 in one place.
 なお、本実施の形態では、針管3の軸に垂直な面方向において、針管3から突起56までの距離は任意に設定してよい。
 また、針管3の軸方向において、針先3Aから軟材57までの距離が0.5mm以上3mm以下であれば、針先3Aを軟材57に穿刺しなくても、針先3Aに形成された液滴を軟材57に接触させ、軟材57に吸収させることができる。
In the present embodiment, the distance from the needle tube 3 to the projection 56 may be arbitrarily set in the surface direction perpendicular to the axis of the needle tube 3.
If the distance from the needle tip 3A to the soft material 57 is 0.5 mm or more and 3 mm or less in the axial direction of the needle tube 3, the needle tip 3A is formed on the needle tip 3A without puncturing the soft material 57. The liquid droplets can be brought into contact with the soft material 57 and absorbed by the soft material 57.
 以上、薬剤注射装置の実施の形態について説明した。本技術は上記実施の形態にとらわれることなく、特許請求の範囲に記載した本技術の要旨を逸脱しない限りにおいて、考えられる種々の形態を含むものである。 The embodiment of the drug injection device has been described above. The present technology is not limited to the above-described embodiments, and includes various conceivable forms without departing from the gist of the present technology described in the claims.
 1,1A・・・注射針組立体、2・・・シリンジ、3・・・針管、3A・・・針先、3a・・・刃面、3B・・・基端、4・・・針ハブ、5,5a・・・キャップ、6・・・第1部材、7・・・弾性部材、8・・・第2部材、9・・・ベース部、9a,9b,11a,12a,15b,16a,16b,42a,70a,70b・・・面、10・・・調整部、10a・・・針突出面、11・・・安定部、12・・・ガイド部、13・・・貫通孔、14・・・接着剤、15・・・注入用孔、16・・・接続片、17,18・・・通気孔、19・・・挿入部、19a,20a・・・筒孔、20・・・嵌入部、21・・・固定片、22・・・溝、23・・・ストッパー、24・・・係合部、24a,24b・・・係合面、25・・・ハブ側表示部、41・・・シリンジ本体、41a・・・端面、42・・・排出部、42b・・・排出口、43・・・ねじ部、44・・・シリンジ側表示部、46・・・液室、51・・・第1筒部、51a・・・筒孔、52・・・第2筒部、52a・・・筒孔、52b,53b・・・内面、52c・・・突出部、53・・・底部、53a・・・凹部、53c・・・突出部、54・・・膨出部、55,55A・・・回収部、55a・・・筒孔、56・・・突起、56a・・・筒孔、57・・・軟材、70・・・本体部、71・・・挿通孔、72,73・・・フランジ部、74・・・ベース側離間部、75・・・シリンジ側離間部、76・・・密着部、77・・・針側弁体部、80・・・薬剤、81・・・液滴、82・・・液滴、100,110,200・・・薬剤注射装置 DESCRIPTION OF SYMBOLS 1,1A ... Injection needle assembly, 2 ... Syringe, 3 ... Needle tube, 3A ... Needle tip, 3a ... Blade surface, 3B ... Base end, 4 ... Needle hub 5, 5a ... cap, 6 ... first member, 7 ... elastic member, 8 ... second member, 9 ... base portion, 9a, 9b, 11a, 12a, 15b, 16a , 16b, 42a, 70a, 70b... 10, adjusting portion, 10a... Needle protruding surface, 11... Stabilizing portion, 12... Guide portion, 13. ... Adhesive, 15 ... Injection hole, 16 ... Connection piece, 17,18 ... Vent hole, 19 ... Insertion part, 19a, 20a ... Cylinder hole, 20 ... Insertion part, 21 ... fixed piece, 22 ... groove, 23 ... stopper, 24 ... engagement part, 24a, 24b ... engagement surface, 25 ... hub side display part 41 ... syringe body, 41a ... end face, 42 ... discharge part, 42b ... discharge port, 43 ... screw part, 44 ... syringe side display part, 46 ... liquid chamber, 51 ... 1st cylinder part, 51a ... cylinder hole, 52 ... 2nd cylinder part, 52a ... cylinder hole, 52b, 53b ... inner surface, 52c ... protrusion part, 53 ...・ Bottom part, 53a ... concave part, 53c ... projecting part, 54 ... bulging part, 55, 55A ... recovery part, 55a ... cylindrical hole, 56 ... projection, 56a ... Cylindrical hole, 57 ... Soft material, 70 ... Main body, 71 ... Insertion hole, 72,73 ... Flange part, 74 ... Base side separation part, 75 ... Syringe side separation part , 76 ... adhesion part, 77 ... needle side valve body part, 80 ... medicine, 81 ... droplet, 82 ... droplet, 100, 110, 200 ... Agent injection device

Claims (5)

  1.  皮膚に穿刺される針先と、前記針先と反対側の基端を有する針管と、
     内部に充填された薬剤と、前記薬剤を排出する排出部とを有し、内部から空気が排出された状態のシリンジの前記排出部が嵌入される嵌入部と、前記針管を保持して前記針管の基端を前記嵌入部に位置させる保持部と、を有する針ハブと、
    前記針管の前記針先を覆うキャップと、
     を備え、前記キャップの内壁面に、前記針先から漏れ出た液滴を回収する回収部が設けられたことを特徴とする
     注射針組立体。
    A needle tip punctured into the skin, a needle tube having a proximal end opposite to the needle tip,
    The needle tube that holds the needle tube, the insertion portion into which the discharge portion of the syringe in a state where air is discharged from the inside has a medicine filled inside and a discharge portion that discharges the medicine A needle hub having a holding portion that positions the proximal end of the fitting portion on the fitting portion,
    A cap that covers the needle tip of the needle tube;
    The injection needle assembly is characterized in that a recovery part for recovering the liquid droplet leaking from the needle tip is provided on the inner wall surface of the cap.
  2.  前記回収部は、前記針先の周囲を覆う筒状に形成されていることを特徴とする請求項1に記載の注射針組立体。 2. The injection needle assembly according to claim 1, wherein the recovery part is formed in a cylindrical shape covering the periphery of the needle tip.
  3.  前記回収部は、前記薬剤を吸収する吸収体を有することを特徴とする請求項1に記載の注射針組立体。 2. The injection needle assembly according to claim 1, wherein the recovery unit includes an absorber that absorbs the drug.
  4.  前記針先は、前記吸収体に接触していることを特徴とする請求項3に記載の注射針組立体。 The needle assembly according to claim 3, wherein the needle tip is in contact with the absorber.
  5.  皮膚に穿刺される針先と、前記針先と反対側の基端を有する針管と、
     内部に充填された薬剤と、前記薬剤を排出する排出部とを有し、内部から空気が排出されたシリンジと、
     前記シリンジの前記排出部が嵌入される嵌入部と、前記針管を保持して前記針管の基端を前記嵌入部に位置させる保持部と、を有する針ハブと、
     前記針管の前記針先を覆い、前記針先を保護するキャップと、
     を備え、前記キャップの内壁面に、前記針先から漏れ出た液滴を回収する回収部が設けられたことを特徴とする
     薬剤注射装置。
    A needle tip punctured into the skin, a needle tube having a proximal end opposite to the needle tip,
    A syringe having a medicine filled therein, a discharge part for discharging the medicine, and air discharged from the inside;
    A needle hub having an insertion portion into which the discharge portion of the syringe is inserted, and a holding portion that holds the needle tube and positions a proximal end of the needle tube at the insertion portion;
    A cap that covers the needle tip of the needle tube and protects the needle tip;
    And a recovery unit that recovers the liquid droplet leaking from the needle tip is provided on the inner wall surface of the cap.
PCT/JP2012/055940 2011-05-20 2012-03-08 Injection needle assembly and drug injection device WO2012160855A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011113421 2011-05-20
JP2011-113421 2011-05-20

Publications (1)

Publication Number Publication Date
WO2012160855A1 true WO2012160855A1 (en) 2012-11-29

Family

ID=47216944

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/055940 WO2012160855A1 (en) 2011-05-20 2012-03-08 Injection needle assembly and drug injection device

Country Status (1)

Country Link
WO (1) WO2012160855A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11511358A (en) * 1995-08-22 1999-10-05 エム ディー シー インベストメント ホールディングス,インコーポレイテッド Prefilled drug solution injection ampule with retractable injection needle
JP2002078799A (en) * 2000-09-08 2002-03-19 Terumo Corp Liquid injection appliance
WO2011040263A1 (en) * 2009-09-30 2011-04-07 テルモ株式会社 Injection needle assembly and drug injection device

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11511358A (en) * 1995-08-22 1999-10-05 エム ディー シー インベストメント ホールディングス,インコーポレイテッド Prefilled drug solution injection ampule with retractable injection needle
JP2002078799A (en) * 2000-09-08 2002-03-19 Terumo Corp Liquid injection appliance
WO2011040263A1 (en) * 2009-09-30 2011-04-07 テルモ株式会社 Injection needle assembly and drug injection device

Similar Documents

Publication Publication Date Title
JP6284595B2 (en) Injection needle assembly and drug injection device
JP5667571B2 (en) Injection needle assembly and drug injection device
JP5756793B2 (en) Injection needle assembly and drug injection device
WO2011122395A1 (en) Prefilled syringe
JP5719522B2 (en) Drug administration device and drug injection device
WO2011125561A1 (en) Prefilled syringe and method for assembling prefilled syringe
WO2011040219A1 (en) Syringe needle assembly and medication injection device
WO2011040221A1 (en) Syringe needle assembly and medication syringe device
WO2011125560A1 (en) Prefilled syringe
JP5894582B2 (en) Injection needle assembly and drug injection device
WO2011122393A1 (en) Prefilled syringe
WO2012147408A1 (en) Hypodermic needle assembly and drug injection device
WO2011068131A1 (en) Prefilled syringe
WO2012153563A1 (en) Injection needle assembly and drug injection device
WO2011040222A1 (en) Hypodermic needle assembly and medicine injection device
JP2011115345A (en) Prefilled syringe
WO2012147415A1 (en) Injection needle assembly and drug injection device
WO2012157318A1 (en) Injection needle assembly and drug-injecting device
WO2012160855A1 (en) Injection needle assembly and drug injection device
WO2012160852A1 (en) Injection needle assembly and drug injection device
JP2011212183A (en) Prefilled syringe
WO2012157323A1 (en) Injection needle assembly and drug injection device
JP2011212184A (en) Prefilled syringe
WO2012157313A1 (en) Injection needle unit
JP2012010970A (en) Drug injection apparatus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12788902

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12788902

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP